CA2468453A1 - Method of preparing a transgenic non-human animal expressing p25 - Google Patents
Method of preparing a transgenic non-human animal expressing p25 Download PDFInfo
- Publication number
- CA2468453A1 CA2468453A1 CA002468453A CA2468453A CA2468453A1 CA 2468453 A1 CA2468453 A1 CA 2468453A1 CA 002468453 A CA002468453 A CA 002468453A CA 2468453 A CA2468453 A CA 2468453A CA 2468453 A1 CA2468453 A1 CA 2468453A1
- Authority
- CA
- Canada
- Prior art keywords
- tau
- transgenic
- human
- protein
- cdk5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title description 27
- 108010026424 tau Proteins Proteins 0.000 claims description 74
- 102000013498 tau Proteins Human genes 0.000 claims description 73
- 210000004556 brain Anatomy 0.000 claims description 29
- 230000026731 phosphorylation Effects 0.000 claims description 22
- 238000006366 phosphorylation reaction Methods 0.000 claims description 22
- 108020004511 Recombinant DNA Proteins 0.000 claims description 7
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 5
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 5
- 108010091047 neurofilament protein H Proteins 0.000 claims description 5
- 208000002109 Argyria Diseases 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 101710142246 External core antigen Proteins 0.000 abstract description 60
- 101710152529 Fibrohexamerin Proteins 0.000 abstract description 60
- 101710147507 Neutrophil gelatinase-associated lipocalin Proteins 0.000 abstract description 60
- 102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 abstract description 57
- 101150053721 Cdk5 gene Proteins 0.000 abstract description 35
- 108700019146 Transgenes Proteins 0.000 abstract description 31
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 29
- 238000011830 transgenic mouse model Methods 0.000 abstract description 25
- 210000002569 neuron Anatomy 0.000 abstract description 23
- 230000016273 neuron death Effects 0.000 abstract description 19
- 101000679400 Homo sapiens Tubulin polymerization-promoting protein Proteins 0.000 abstract description 18
- 210000004727 amygdala Anatomy 0.000 abstract description 18
- 102000051498 human TPPP Human genes 0.000 abstract description 18
- 230000006951 hyperphosphorylation Effects 0.000 abstract description 17
- 241000699660 Mus musculus Species 0.000 abstract description 16
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 abstract description 14
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract description 11
- 229910052709 silver Inorganic materials 0.000 abstract description 11
- 239000004332 silver Substances 0.000 abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 239000012190 activator Substances 0.000 abstract description 8
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 108010088373 Neurofilament Proteins Proteins 0.000 abstract description 7
- 102000008763 Neurofilament Proteins Human genes 0.000 abstract description 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 abstract description 7
- 210000005044 neurofilament Anatomy 0.000 abstract description 7
- 230000002018 overexpression Effects 0.000 abstract description 7
- 102000001253 Protein Kinase Human genes 0.000 abstract description 6
- 108060006633 protein kinase Proteins 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 abstract description 5
- 210000001103 thalamus Anatomy 0.000 abstract description 5
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 2
- 101100495314 Caenorhabditis elegans cdk-5 gene Proteins 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 230000007505 plaque formation Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 63
- 150000001875 compounds Chemical class 0.000 description 33
- 238000012360 testing method Methods 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 26
- 108090000663 Annexin A1 Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 description 17
- 210000003050 axon Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000003656 tris buffered saline Substances 0.000 description 8
- 210000005056 cell body Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 3
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 3
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 description 3
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 3
- 101000980900 Homo sapiens Sororin Proteins 0.000 description 3
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 102000048091 human CDCA5 Human genes 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 101150073031 cdk2 gene Proteins 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 235000015246 common arrowhead Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- -1 e.g Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101800001151 Protein p25 Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 102220365496 c.38C>G Human genes 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 102000021160 microtubule binding proteins Human genes 0.000 description 1
- 108091011150 microtubule binding proteins Proteins 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007137 neurofibrillary pathology Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide.
The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid p peptides and hyperphosphorylated tau, respectively. While animal models for plaque formation exist, there is no animal model that recapitulates the formation of NFTs. This invention provides' transgenic mice that overexpress human p25, an activator of cdk5, resulting in tau that is hyperphosphorylated at AD-relevant epitopes.
Deposition of tau is detected in the amygdala, thalamus and cortex. Increased phosphorylated neurofilament, silver-positive neurons and neuronal death are also observed in these regions.
We conclude that the overexpression of p25, an activator of cdk5, is sufficient to produce hyperphosphorylation of tau and neuronal death. The p25 transgenic mouse represents the first model for tau pathology in AD.
The two neuropathological lesions associated with Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles (NFTs), composed predominantly of amyloid p peptides and hyperphosphorylated tau, respectively. While animal models for plaque formation exist, there is no animal model that recapitulates the formation of NFTs. This invention provides' transgenic mice that overexpress human p25, an activator of cdk5, resulting in tau that is hyperphosphorylated at AD-relevant epitopes.
Deposition of tau is detected in the amygdala, thalamus and cortex. Increased phosphorylated neurofilament, silver-positive neurons and neuronal death are also observed in these regions.
We conclude that the overexpression of p25, an activator of cdk5, is sufficient to produce hyperphosphorylation of tau and neuronal death. The p25 transgenic mouse represents the first model for tau pathology in AD.
Description
.1-The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 polypeptide, an activator of the protein kinase cdk5. The invention also provides non-human animals and cells comprising a transgene encoding a p25 polypeptide and further comps ising functional overexpression of p25, the p25 transgene and targeting constructs used to produce such transgenic cells and animals, transgenes encoding human p25 polypeptide sequences and methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling neurodegenerative disease such as Alzheimer's disease and p25/cdk5 biochemistry in vivv.
Throughout the speafication, s number of pubkcations are cited. A complete listing of the p~a~~ ~ter in the speafi~lion.
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder characterized by loss of cognitive function. The primary neuropathologicai lesions in AD are amyloid plaques and neurofibrillary tangles (NFTs). Amyloid plaques are composed primarily of amyloid beta (Ab) peptides, varying in length from 39-42 amino acids, which are derived from amyloid precursor protein (APP) (reviewed in 1 ). NFTs are composed of the microtubule binding protein tau that is hyperphosphorylated at epitopes which exist in a predominantly unphosphorylated state in disease-free brain (2-4). The respective roles that these lesions play in the neuronal loss and dementia observed in patients with AD remain controversial.
The precise mechanism of NFT formation is not Gear but work from many laboratories suggests that hyperphosphoryiation of tau may be an important event. The paired helical filament (PHF) is the fundamental unit of the NFT.
Hyperphosporylation of tau at serine or threonine residues followed by proline (SP or TP), epitopes which are concentrated at the amino and carboxy termini of tau, results in loss of affinity for microtubules, and a presumed concomittant increase in the concentration of cytoplasmic tau (5-8). However, phosphoryiation of tau at serine 262, which is not followed by proline, can also reduce the affinity of tau for microtubules (9). in vitro experiments with purified tau show that in the presence of endogenous rations (e.g., mRNA, heparin sulfate proteoglycan), tau polymerizes to form structures indistinguishable from the PHF seen in AD brain (10,11). The ration-dependent formation of PHF in vitro is independent of the phosphorylation state of tau, suggesting that the key permissive event in initiating PHF formation may be an increase in the cytoplasmic concentration of tau. In support of this hypothesis, recent evidence (12-14) indicates that the mutations in the tau gene associated with susceptibility to a form of inherited l'SERS~DOC~LA:1932~LPRFS'.2Q9X01! DOC ~ I:7763 i PCIOI~:.RFS (NEW PATEN11 dementia called frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), reduce the affinity of tau for microtubules (15). Therefore these mutations, like hyperphosphorylation, may result in an increase in cytoplasmic tau concentrations. In the presence of endogenous cations, this increase is presumed to permit PHF
formation followed by NFT assembly and, ultimately, neuronal death.
As with other phosphoproteins, the phosphorylation state of tau is the sum of protein kinase and protein phosphatase activity. Thus hyperphosphorylation of tau in AD may be due to an increase in kinase activity or a decrease in phosphatase activity. While many protein kinases phosphorylate tau at AD-relevant epitopes in vitro (reviewed in 16,17), only two have been co-purified with microtubules from mammalian brain, GSK3b and cdk5 (18).
To our knowledge, only these two kinases will phosphorylate tau when transfected heterologously into mammalian cells (19,24). We chose to focus on cdk5 vs. GSK3b as the latter plays a role in energy metabolism and is expressed in an active form in all cells, while cdk5 is only active in neurons (vide infra).
The kinase cdk5 is a member of the cyclin-dependent protein kinase family and is expressed in nearly all cells (reviewed in 25,26). Unlike other members of the cdk family, there is no known cyclin which activates cdk5. Rather, the positive allosteric regulators of cdk5 are p35 (27), amino terminal proteolytic fragments of p35, e.g, p25, p23 or p21 (28,29) and p39 (30). These proteins share minimal amino acid sequence homology to cyclins (27-29) but computer modeling and biochemical experiments suggests that the mechanism of activation of cdk5 by p25/35 may be similar to that of cyclin A activation of cdk2 (31-33). The protein p25/35 is expressed predominantly in neurons implying that most cdk5 activity is concentrated in neuronal structures (27,28). The protein p35 has a relatively short half life within cells and is rapidly ubiquitinated, suggesting tight regulation of cdk5 activity in neurons (34). The kinase cdk5 plays a pivotal role in neuronal development as evidenced by the abnormal corticogenesis and perinatal lethality of cdk5 knockout mice (35) and the disturbances in neuronal migration and early death in p35 knock-out mice (36).
In developmental studies in rodents, the peak catalytic activity of cdk5 occurs at E11 or 12, lending further support for the role of cdk5 in neurogenesis (37,38).
Furthermore, in primary cultured neurons, cdk5/p35 is localized to growth cones suggesting a role in neurite outgrowth (39). Recently, evidence of signaling pathways which may modulate cdk5 activity have emerged. For example, it has been demonstrated that cdk5/p35 interacts with Rac and modulates PAK activity (40), and that laminin-enhanced outgrowth of cerebellar neurons is disrupted by suppression of p35 expression (41 ). A few substrates for cdk5 have been identified and are consistent with the presumed role in neurite outgrowth and plasma membrane dynamics. These include cytoskeletal proteins such as tau (42-45) and neurofilament (46-48), synaptic vesicle proteins such as synapsin and Munc-18 (49,50) and the retinoblastoma protein (51 ). Nevertheless, neither a clear picture of a signal transduction pathways) which regulates cdk5/p35 activity nor the role of both cdk5/p35 in mature brain have been elucidated.
A clear picture of the protein kinases responsible for the hyperphosphorylation of tau in AD is also lacking. However, evidence that cdk5 may a play a pathological role is accumulating. For example, in in vitro studies, cdk5 will phosphorylate up to eight different epitopes of tau, including those associated with AD and known to decrease the affinity of tau for microtubules (42-45). Additionally, heterologous co-transfection of cdk51p25 with tau into mammalian cells also results in phosphorylation of several of these epitopes (24). Finally, immunohistochemical evidence suggests that cdk5 is proximal to NFTs in AD
brain (52,53).
The development of experimental models of Alzheimer's disease that can be used to define further the underlying biochemical events involved in AD pathogenesis would be highly desirable. Such models could be employed, in one application, to screen for agents that alter the degenerative course of AD. For example, a model system of AD could be used to screen for environmental factors that induce or accelerate the pathogenesis of AD.
Alternatively, an experimental model could be used to screen for agents that inhibit, prevent, or reverse the progression of AD. Such models could be employed to develop pharmaceuticals that are effective in preventing, arresting or reversing AD. Only humans and aged non-human primates develop any of the pathological features of AD. The expense and difficulty of using primates and the length of time required for developing the AD pathology makes extensive research on such animals prohibitive. Rodents do not develop AD, even at an extreme age.
Despite various reports that certain treatments result in hyperphosphorylation of tau and/or neuronal death associated with the phosphorylation of tau, there is a need in the art for transgenic non-human animals which can produce hyperphosphorylation of tau and associated neuronal death.
Based on the above, it is clear that a need exists for nonhuman cells and nonhuman animals which produce hyperphosphorylation of tau and neuronal cell death.
Thus, it is an object of the invention herein to provide methods and compositions for transferring transgenes and homologous recombination constructs into mammalian cells, especially into embryonic stem cells. It is also an object of the invention to provide transgenic non-human cells and transgenic nonhuman animals harboring transgenes resulting in the increased expression of p25, an activator of cdk5. Of further interest to the present invention are the application of such transgenic animals as in vivo systems for screening test compounds for the ability to inhibit or prevent the production of hyperphosphorylated tau and associated neuronal death. It is desirable to provide methods and systems for screening test compounds -a-for the ability to inhibit or prevent the phosphorylation of tau and associated neuronal death.
In particular, it is be desirable to base such methods and systems on inhibition of cdk51p25.
where the test compound blocks phosphorylation of tau mediated by cdk5lp25, the test compound also blocks neuror>ai death. Such methods and transgenic animals should provide a rapid, economical and suitable way for screening large numbers of test compounds.
We overexpressed human p25 in the brains of mice to determine if an inaease in cdk5 activity would result in the hyperphosphorylation of tau at AD-relevant epitopes, and if this hyperphosphorylation would lead to neuronal death. In the brains of p25 transgenic mice, both tau and neurofilament are hyperphosphorytated, and many silver-positive neurons with tangle-like inGusions are present. The silver-positive neurons suggest ongoing neuronal death. These results demonstrate that overexpression of an activator of cdk5 is sufficient to produce tau and neurofilament phosphorylation and silver-positive neurons which are very similar to those seen in AD. The p25 transgenic mouse may serve as a model for the neurofibrillary pathology and neuronal death seen in AD.
Summary of the Invention In one embodiment. the present invention is directed to a purfied and isolated recombinant poiynuueoa0e comprising a neuron speafic enotase promoter operably linked to a p25 encoding sequence.
In a preferred embodiment, the present mention is directed to recombinant DNA
wherein said sequence encoding said p25 protein s genomic DNA.
In another preferred embodiment, the present invention is directed to recombinant DNA wherein said sequence encoding said p25 protein ~s cDNA.
In still another preferred embodiment, the present invention is directed to recombinant DNA wherein said sequence is that of SEA ID NO: a In yet another embodiment, the present invention is directed to a vector comprising recombinant DNA according to the present invention.
In another embodiment, the present invention is directed to eukaryotic cell comprising recombinant ONA according to the present invention.
In another embodiment, the present invention is directed to a transgenic non-human animal, or progeny thereof, whose germ cells and somatic cells express recombinant DNA
according to the present invention.
In a preferred embodiment, the present invention is directed to a transgenic non-human animal, or progeny thereof, which is a mouse.
In a further embodiment, the present invention is directed to a method for treating an animal having a disease characterized by the expression of a p25 fragment of a human cdKS
gene comprising administering a therapeutically effective amount of an inhibitor of said p25 fragment.
In another embodiment, the present invention is directed to a method for determining the ability of a compound to inhibit the expression of a p25 protein comprising the steps of:
a. creating a transgenic non-human animal by stably incorporating into the embryonic stem cells of said animal a recombinant polynucleotide composing a neuron-speicific enolase promoter operably linked to an encoding sequence for p25;
b. growing said embryonic stem cells into a mature transgenic non-human animal;
c. administering to said transgenic non-human animal the compound of interest;
d. measuring the inhibition of said p25 protein by said compound.
In still another embodiment the present invention is directed to a method for generating data to determining the ability of a compound to inhibit the expression of a p25 protein comprising the steps of:
a. creating a transgenic non-human animal by stably incorporating into the embryonic stem cells of said animal a recombinant polynucleotide comprising a neuron-speicific enolase promoter operably linked to an encoding sequence for p25;
b. growing said embryonic stem cells into a mature transgenic non-human animal;
c. administering to said transgenic non-human animal the compound of interest;
d. measuring the inhibition of said p25 protein by said compound;
e. using the data derived from said inhibition to synthesize compounds capable of inhibiting said p25 protein.
Figure 1A. Western blots of the amygdala (1), thalamus (2) and cortex (3) from 3 wild type mice were probed with an antibody specific for p25 and p35/39 (generous gift of L.-H.
Tsai, Harvard Medical School Cambridge, MA).
Figure 1 B. Western blots of the amygdala (1 ), thalamus (2) and cortex (3) from 3 p25 transgenic mice were probed with the same antibody as in FIG 1A.
Expression of the transgene, p25, is apparent in the transgenic but not wild type mice.
Figure 2 displays a four month old transgenic mouse brain imunopositive for AT-8 (a commercially available antibody which specifically recgnoizes phopho-serine 202/205 of tau) specific in the rostral portion of the amygdala. Neuronal cell bodies with accompanying axons (arrows) are positive. Several dark-brown positive cells are seen in this field.
Figure 3 shows a four month old wild-type mouse brain minimally positive for AT-8 in the rostra) portion of the amygdala. A cell body exhibits non-specific positivity (arrow) due to the secondary antibody.
Figure 4 shows a four month old transgenic mouse brain demonstrating PHF-13 (an antibody which recognizes phospho-serine 396/404 of tau; (gift from Dr. V.
Lee, U. of Pennsylvania) immunopositivity in the rostra) portion of the amygdala.
Neuronal cell body with a thickened axon (arrow) is positive. Positive neuronal cell body (arrow head) with possible swollen/atrophied axon.
Figure 5 shows a four month old wild-type mouse brain minimally positive for in the rostra) portion of the amygdala. Cell bodies exhibit non-specific positivity (arrows) due to the secondary antibody.
Figure 6 shows a four month old transgenic mouse brain immunopositive for total tau (an antibody which recongnizes total tau commercially available from Accurate Chemical and Scientific Corp Westbury, N.Y.) in several cell bodies of the rostra) amygdala (examples marked by arrows).
Figure 7 shows a four month old wild-type mouse brain immunopositive for tau in axons (arrow heads) of the rostra) amygdala.
Figure 8 shows a four month old transgenic mouse brain reacted with SMI-34 (a commercially available antibody which recognizes phosphorylated neurofilament H protein).
Positive cells (arrows) are seen in the rostra) amygdala.
Figure 9 shows minimal SMI-34 axonal positivity in the rostra) amygdala of a four month old wild-type mouse brain.
Figure 10 shows silver-positive (an indication of disrupted cytoskeleton and neuronal cell death) cell bodies (arrows) in the rostra) amygdala of a four month old transgenic mouse brain.
Figure 11 shows minimal silver positivity of axons in the rostra) amygdala of a four month old wild type mouse.
Figure 12 shows several dilated axons (arrows) that exhibit silver positivity in the spinal cord of a five month old transgenic mouse.
Figure 13 shows several dilated axons (arrows) that exhibit SMI-34 positivity in the spinal cord of a five month old transgenic mouse.
Figure 14 shows that normal axons in the spinal cord of a six month old wild-type mouse are negative for SMI-34.
Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, nucleic acid chemistry and hybridization, biochemistry, histology and immunocytochemistry described below are those well known and commonly described in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, cell culture, transgene incorporation, Western blotting, immunocytochemistry and histological techniques such as silver staining. The techniques and procedures are generally performed according to conventional methods in the art and various general refererxes which are provided throughout this specification. The procedures therein are well known in the art and are provided for the convenience of the reader.
In accordance with the foregoing objects, in one aspect of the invention are provided nonhuman animals harboring at least one copy of a transgene comprising a polynucleotide sequence that encodes a heterologous protein operably linked to regulatory elements that are capable of expressing the heterologous protein in the transgenic nonhuman animal. Said heterologous polypeptide is a truncated portion of the p35 cyclin dependent kinase 5 (cdk5) regulatory protein (27,28). The truncated heterologous polypeptide has the first 98 N-terminal amino acids removed and has a molecular weight of approximately 25,000 daltons. This novel polypeptide will be referred to as p25. Typically, the nonhuman transgenic animal is a mouse and the heterologous gene is the human p25 sequence. Transgenes are typically cDNR
sequences that have been operably linked to cis-acting regulatory sequences that direct expression in the host transgenic mammal in cell-type specific manner, typically in neurons.
Typically, the transgene will be incorporated into the host chromosomes in random, non-targeted fashion. The invention further provides that the nonhuman, transgenic animal harboring at least one copy of the heterologous p25 sequence transgene or gene targeting vector of the invention either non-homologously or homologously integrated into the chromosomal location express the p25 truncated polypeptide. Transgenic animals are typically produced by introduction of a transgene by microinjection into pronuGei of one-cell embryos or a targeting vector into the host by electroporation, lipofection, or viral transfection of embryonic stem (ES) cells. The transgenic animals that express the p25 polypeptide are suitable for use as models of disease and screening of potential therapeutic compounds including small molecules, proteins and polynucleotides. The invention also provides nonhuman or human cell lines to be derived by transformation of established cell lines or primary cell lines established directly from the nonhuman transgenic animal, for example neurons. It is obvious that the transgenic nonhuman animal can have additional genetic modifications by transgenic art or through traditional matings with other transgenic or naturally occurring animals to produce novel animals that serve as alternative disease models, drug saeens or other applications. This includes the inactivation of the murine endogenous p35 gene through gene targeting in ES cells and resultant murine p35-deficient mice that becomes the preferred host for expression of the human p25 heterologous polypeptide.
Such _8_ heterologous transgenes may be integrated in nonhomologous chromosomal locations in the transgenic animal, typically derived by pronuclear injection or may be integrated by gene targeting in ES cells by methods to inactivate the murine p35 gene and add linked sequences to direct expression of the heterologous human p25 sequences.
In general, the invention encompasses methods for the generation and characterization of transgenic animals that express the human p25 polypeptide, a proteolytic fragment of p35, both of which are an allosteric activators of cyclin dependent kinase 5 (cdk5).
The transgenic animals express this human protein in the presence of the endogenous homologue. The techniques and procedures are performed according to established protocols that are generally considered to be routine methods in the art and references are provided within this specification. The protein kinase cdk5 when associated with an allosteric activator, e.g., p35 or p25 is reported in the literature to phosphorylate tau in vitro and in whole cells (see Background of the Invention). The transgenic mice thus produced establish the role of the human p25 in the formation of hyperphosphorylated tau in neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, amyelolateral sclerosis, Huntington's chorea, stroke, traumatic brain injury, Pick's disease, neuraxonal dystrophy, multiple sclerosis, motor neuron disease, and spinocerebellar degeneration and other neurodegenerative diseases. It is apparent that the preparation of other transgenic animals that express the human p25 protein is easily accomplished including rats, hamsters, guinea pigs and rabbits. The transgenic animals that express the human p25 protein can be monitored for the level of expression and tau phosphorylation. It will be appreciated that under different conditions the level of expression and degree of tau phosphorylation will be inhibited in such an animal model. In particular, the screening of therapeutic agents that inhibit the activity of the human p25 protein will be greatly facilitated in animal models. It is apparent that the development of cell lines from the affected transgenic animals, (e.g., neurons) will improve the throughput in which biochemical and pharmacological analysis of the human p25 protein can be assessed.
Particularly preferred animal models for p25 overexpression are transgenic anmals which express p25 as described above. Such transgenic animals, particularly transgenic mice according to this invention, produce high quantities of p25 and hyperphosphorylated tau and neuronal death which may be detected according to the methods of the present invention.
In accordance to this invention particular, the overexpression of p25 will be equal to or greater than endogenous p25 expression in such animals. Further, this level of p25 overexpression results in tau hyperphosphorylation which is minimal in wild type animals.
With such elevated levels of p25, monitoring of hyperphosphorylation of tau and neuronal death is greatly facilitated. In particular, screening for compounds and other therapies for inhibiting tau _g_ phosphorylation are greatly simplified in animals overexpressing p25 according to this invention.
Agents are administered to test animals, such as test mice, which are transgenic and which overexpress p25. Particular techniques for producing transgenic mice which overexpress p25 are described below. It will be appreciated that the preparation of other transgenic animals overexpressing p25 may easily be accomplished, including rats, hamsters, guinea pigs, rabbits, and the like. In light of this disclosure, the effect of test compounds on the hyperphosphorylation of tau in the test animals may be measured in various specimens from the test animals.
The effect of test agents on hyperphosphorylation of tau may be measured in various specimens from the test animals. In all cases, it will be necessary to obtain a control value which is characteristic of the level of tau phosphorylation and neuronal death in the test animal in the absence of the test compound(s). In cases where the animal is sacrificed, it will be necessary to base such control values on an average or a typical value from other test animals which have been transgenically modified to overexpress p25 but which have not received the administration of any test compounds or any other substances expected to affect the level of tau phosphorylation or neuronal death. Once such control level is determined, test compounds can be administered to additonal test animals, where deviation from the average control value indicates that the test compound had an effect on the tau phosphorylation or neuronal death in the animal. Test substances considered positive, i.e., likely to be beneficial in the treament of AD or other neurodegenerative diseases, will be those which are able to reduce the level of tau phosphorylation or neuronal death preferably by at least 20% and most preferably by 80%. In addition there may be paired helical or straight filament formation in transgenic animals which overexpress p25 and display tau hyperphosphorylation.
In these cases, test compounds can be administered to test animals and the reduction of filament formation monitored as a result of exposure to the compound. In addition, there may be behavioral alterations in the transgenic animals which overexpress p25 and display tau hyperphosphorylation. In these cases it will be necessary to obtain a control value from live animals performing a behavioral task (e.g., the measurement of locomotor activity) in the test animal in the absence of test compound(s). Such a control will also be determined in non-transgenic, wild type mice. The difference between the wild type and transgenic mice will serve as the outcome measure for the effects of compounds. Once such control levels are determined, test compounds can be administered to additional test animals, where reduction in or reversal of the difference between the wild type and transgenic mice indicates that test compound has an effect on the behavioral test being measured. Test substances considered positive, i.e., likely to be beneficial in the treament of AD or other neurodegenerative diseases, preferably will be those which are able to reverse or, substantially reverse, or favorably modify the behavioral abnormality in the transgenic animal to the level found in wild type mice.
Test agents will be defined as any small molecule, protein, polysaccharides, deoxy or r~ortxrcleotides, or any combination !hereof that when added to the cell culture a animal will not adversely interfere with the colt a animal viability. Agents that alter the level of human p25 express'ron and tau phosphorylation will be considered as candidates for further evaluation as potential therapeutics. The test compound will typically be administered to transgenic animals at a dosage of from 1 ngJkg to 100mgltcg, usually from 1 Ouglkg to 32 mgJkg.
Test compounds which are able to inhibit phosphorylation of tau are considered as candidates for fuller determinations of the ability to block tau phosphorylation in animals and humans. Inhibition of tau phosphorylation indicates that cdk5lp25 activity has been at least partly blocked, reducing the amount of cdk5lp25 available to phosphorylate tau.
The present invention further comprises pharmaceutical compositions incorporating a compound selected by the above-described method and including a pharmaceutically acceptable carrier. Such pharmaceutical compositions should contain a therapeutic or prophylactic amount of at least one compound identified by the method of the present invention. The pharmaceutically acceptable carrier can be any compatible, non-toxic substance suitable to deliver the compound or compounds to an intended host.
Sterile water, alcohol, fats, waxes and inert solids may be used as the carrier.
Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like may also be incorporated into the pham~aceutical compositions. Preparation of pharmaceutical compositions incorporating active agents is well described in the medical and scientific literature. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16°' Ed., 1 ssz.
The pharmaceutical compositions just described are suitable for systemic administration to the host, including both parenteral, topical, and oral administration. The pharmaceutical compositions may be administered parenterally, i.e., subcutaneously, intramuscularly or intravenously. Thus, the present invention provides compositions for administration to a host where the compositions comprise a pharmaceutically acceptable solution of the identified compound in an acceptable carrier, as described above.
Commercial Research and Screening Uses Non-human animals comprising transgenes which encode p25 can be used commercially to screen for agents having the effect of preventing or reducing the phosptmrylation of tau and neuronal death. Such agents can be developed as pharmaceuticals for treating hyperphosphorylation of tau and AD amongst other neurodegenerative diseases. For example, the p53 knockout mice of Donehower et al. (54) have found wide acceptance as commercial prouducts for carcinogen screening and the like.
The transgenic animals of the present invention exhibit abnormal tau phosphorylation and can be used for pharmaceutical screening and as disease models for neurodegenerative diseases and cdk5/p25 and tau biochemistry. Such animals have many uses including but not limited to identifying compounds that affect tau hyperphosphorylation; in one variation, the agents are thereby identified as candidate pharmaceutical agents. The transgenic animals can also be used to develop agents that modulate cdk5 or p25 expression and or stability;
such agents can serve as therapeutic agents to treat neurodenerative diseases. The p25 overexpressing mice of the invention can also serve as disease models for investigating tau-related pathologies (e.g., AD, Pick's disease, Parkinson's disease, frontal temporal lobe dementia associated with chromosome 17, stroke, traumatic brain injury, mild cognitive impairment and the like). Such transgenic animals can be commercially marketed to researchers, among other uses.
Having described the invention in general terms, reference is now made to specific examples. It is to be understood that these examples are not meant to limit the present invention, the scope of which is to be determined by the appended claims.
The plasmid pNSE-p25 (rat neuron specific enolase promoter, human p25 transgene) contains DNA from 4 different sources: the rat neuron specific enolase promoter; the human cDNA for the p25 catalytic fragment of the p35 protein; the SV40 polyadenylation signal sequence and a commercially available plasmid vector. The transgene is isolated by BamH1 restriction enzyme digestion of pNSE-p25. This restriction digest releases the NSE-p25 transgene (3212 bp) from the plasmid cloning vector pSP72 (2462 bp) (Promega, Madison, WI). The rat Neuron Specific Enolase (NSE) promoter sequence is 1826 by (SEQ
ID NO: 1 ) and has been demonstrated to efficiently express DNA coding sequences in neurons of transgenic mice (55). The coding region for the human p25 sequence is 633 bp.
(SEQ ID NO:
2). The 3-prime untranslated and SV40 polyadenylation sequence are 688 by (SEQ
ID NO:
3). The microinjected NSE-p25 transgene is 3212 by (SEQ ID NO: 4). Enzymatic reactions of recombinant DNA, including ligations, restriction endonuclease digestions, DNA
synthesis reactions, single strand fill-in reactions, and bacterial transformations performed are well established procedures as described by Sambrook, J., Fritsch, E.F. and Maniatis, T.
Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Press, New York, 1989.
The SV 40 polyadenylation sequence (SEQ ID NO: 3) was cloned into the commercially available plasmid pSP72 (SEQ ID NO: 5) at Xba1 and BstX1 sites.
This plasmid, designated pSP-SVpA, served as the backbone vector for the construction of the NSE-p25 transgene plasmid. The cDNA for the human p25 catalytic fragment was derived using polymerase chain reaction (PCR). The human p35 full length cDNA was used as the template for amplification of the p25 insert. We received the p35 template DNA
from Dr. David Auperin of Pfizer; the human p35 sequence was cloned into the EcoR1 site of the pFastBacl, baculoviral expression vector (Gibco-BRL, Gaithersburg, MD). The PCR primers were designed to have Not1 restriction sites outside the coding sequence to facilitate tsansgene construction. The forward primer also introduced a new ATG start codon adjacent to the GCC
(Ala codon at position 99 of the human p35 sequence). The primers (submitted in 5-prime to 3-prime orientation) were p25-forward:
GCGGCCGCATGGCCCAGCCCCCACCGGCCCAGCCGCCTGCA
(SEO ID NO: 6) and p25-reverse:
CTCCTCCTAGGCCTGGAATCGGTGAGGCGGCCGC (SEQ ID NO: 7). The ATG is introduced start codon, the TGA is the stop codon and the GCGGCCGC are the Not1 restriction sites added to the PCR primers. The resulting PCR product is 648 by containing the entire 633 by human p25 cDNA sequence with engineered ATG start site (SEQ
ID NO: 2) and an additional 15 by from addition of the Not 1 cloning sites. The 648 by fragment was subcloned into the pCR2.1 (Invitrogen, Carlsbad, CA) vector for verification of sequence prior to use as insert in the final transgene. The confirmed 648 by Not 1 fragment was ligated into the Not 1 restriction site of pSP-SVpA producing the plasmid pSP-SVpA:p25. The rat Neuron Specific Enolase (NSE) promoter was isolated from the plasmid pNSE-IacZ
obtained from Dr.
J.G. Sutcliffe of the Research Institute of Scripps Clinic (LaJolla, CA). The rat NSE promoter sequence (SEQ ID NO: 1 ) was isolated by EcoR1 and Hind III restriction digestion of the pNSE-IacZ plasmid. The 1.8 kb fragment was extracted by agarose gel electrophoresis and purified. The 5-prime single strand overhangs generated by the restriction enzymes were filled by Klenow reaction to produce the rat NSE promoter fragment with double stranded blunt ends. The 1826 by rat NSE blunt end promoter fragment was blunt end ligated into the Sma 1 restriction site of pSP-SVpA:p25. The correct orientation of the rat NSE
promoter within the pSP-SVpA:p25 was verified by double restriction digests of BamH1 and Xhol.
Plasmids with the correct orientation were assigned the designation as pNSE-p25. The entire sequence of the 3212 by NSE-p25 transgene (SEQ ID NO: 4) was analyzed and verified by automated sequencing on ABI 373 sequences (Foster City, CA) using the standard dye-terminator chemistry protocol outlined by ABI. All plasmids were grown in DHSalpha bacterial cells (Gibco BRL Gaithersburg MD).
Production of transgenic mice overexpressing human p25.
The 3212 by NSE-p25 transgene DNA fragment was excised from the pNSE-p25 plasmid by BamH1 restriction endonuclease reaction. The 3.2 kbp fragment was isolated by electroelution (50V, 3 hrs) after electrophoresis in 1 % agarose gel (FMC
Bioproducts, Rockland ME). The fragment was further purified by on a Schleicher and Schuell (Keene, NH) Elutip-d column following protocols established by the manufacturer for DNA
purification prior to murine embryo microinjection.
Production of transgenic mice by pronuclear microinjection was carried out by published procedures as outlined in Hogan, B. et al Manipulating the Mouse Embryo: A
Laboratory Manual 2nd edition, Cold Spring Harbor Laboratories, New York, 1994.
Pronuclear stage embryos from F1 females mice of the strain FVB/N (Charles River Labs, Wilmington, MA) were obtained after superovulation with 5 international units (IU) of follicle stimulating hormone from pregnant mare serum (Sigma St Louis, Mo.) and 2.5 LU.
human chorionic gonadotropin (Sigma). The actual microinjection procedure was performed as described by Wagner, T. et al. (56) except that the embryos were transferred immediately to pseudopregnant CD-1 recipient females (Charles River Laboratories, Wilmington, MA) for development of embryos to term. Mice resulting from the reimplantation events were tested for the presence of the NSE-p25 transgene by PCR analysis of genomic DNA isolated from tail biopsies at 3 weeks of age. The mice that demonstrated positive for the presence of the NSE-p25 transgene were mated with wild type FVB/N mice (Charles River Laboratories, Wilmington, MA) of the opposite sex. Offspring of these matings were tested for germline transmission by PCR analysis or Southern blot analysis of genomic DNA isolated from tail biopsies at 3 weeks of age. Transgenic lines were produced from 7 founder transgenic mice and were maintained by breeding to wild type FVB/N mice and PCR genotyping for the presence of the NSE-p25 transgene.
The experiments described below were done in mice heterozygous for the inserted transgene. These mice were derived by breeding mice positive for the transgene insert with FVB/N wild-type animals and screening offspring by PCR for presence of the NSE-p25 transgene sequences.
Detection of overexpression of p25 protein.
Western Blot Whole brains from 1 or 4 month old transgenic (Tg) and wild type (wt) mice were removed and snap frozen in liquid nitrogen. Amygdala, thalamus and cortex were dissected and homogenized in 1 ml of lysis buffer (as described in 37). The samples were boiled for 10 minutes and then centrifuged at 13,000 rpm. Protein concentrations of the resulting supernatants were determined by the Pierce BCA method (BCA micro protein assay, catalog #23225, Pierce, Rockford ILL). Ten micrograms of each sample were electrophoresed on an SDS polyacrylamide gel (57) and transferred to ProBlott protein paper for western blot analysis [Western blotting protocols, ECL detection, Amersham Life Science Arlington Heights, ILL (1995)]. Non specific sites were blocked by incubating the blots in 5% nonfat .14-milk in tris-buffered saline (20mM Tris Base, 127 mM NACI, 3.8 mM HCI pH 7.6, Sigma) included 0.1 % tween-20 ITBS~T). Primary ant~odies were diluted in 5% nonfat milklTBS-T.
The blots were pieced in the diluted antibody adutions and rotated fa 1 hr at 23°C. The western blots were then washed fa 30 min in TSS-T. Secondary horseradish peroxidase linked antibodies were diluted in 5% nonfat mi1k1T8S~T. The blots were incubated with the secondary ant~Ody solution and rotated for 45 min at 23°C. The blots were then washed for 30 min in TBS-T. Equal volumes of Amersham's ECL developing solutions A and 8 were moved together. The Western blots were inwbated fa 1 min in the devebping solution. The blots were wrapped in Saran ~ wrap and then exposed to imaging film (Kodak Rochester N.Y.
X-OMAT AR"', anfstog X1651454).
Western blots of the amygdala (1), thalamus (2) and cortex (3) from 3 mice were probed with an antibody specific fa p25 and p35139 (gift of L.-H. Tsai, Harvard Medical School, Figure 1A). While detection of p35139 is apparent, no p25 is detected in wild type mice. When the same analysis is performed in the transgenic mice (Figure 1 t3), robust expression of p25 in addition to the constitutive expression of p35 is detected. These results confirm that expression of the transgene is robust in the p25 transgenic animals.
Silver Stain 8 SMI 34 Immunohistochemistry Tissues collected from scheduled sacrifice mice were perfusion-fixed in situ with 10°k neutral-buffered formalin or 4% paraformaldehyde, whereas tissues collected from mice found dead were immersion faced in formalin. Following fixation, trimmed tissues were dehydrated through graded alcohols and embedded in paraffin. Standard cross sections of brain were identfied by analogy to figures in The Mouse Brain in Sterevtaxic Coordinates (Franklin and Paxinos, 1997). Paraffin sections (8pm thick) were stained with mod~ed Bielschowsky silver stain and, immunohistochemically, with an antibody directed against phosphorylated neurofilament (SMI 34, commercially availaable from Stemberger Monodonals, Inc Lutherville, MD).
Immunohistochemistry For immunohistochemical studies, transgenic and wild type mice were deeply anesthetized with sodium pentobarbital (ti0 mg/kg, i.p.) and perfused through the ascending aorta with 20 ml of 0.1 M NaPO, containing 0.9% NaCI (PBS, 7.4) followed by 30 ml of fucative containing 4% paraformaldehyde in 0.1 M NaPO, (PB, 7.4) buffer. The brains were removed, cryoprotected for 48 hr in PBS containing 20% suaose, frozen in a bed of pulverized dry ice, and then cut into 35 micron secfrons on a sliding microtome. Consecutive 1 in 18 series of sections were collected in 0.1 M PB and processed for immunohistochemistry as described below.
For immunohistochemistry, sections were inarbated for 1 hr in 50 mM Tris buffer, ph 7.4 containing 0.9% NaCI (TBS) and 0.1 % Trilon-X-100'x. The sections were then washed in TBS and inabated for 1 hr in antibody vehicle (4% goat or horse serum, 0.1 %
Trwort-X-100~" in TBS). After additional washes in T13S, sections were incubated overnight at 4°C in vehicle containing the primary antibody.
Fdlowing overnight incubation in the primary antibody, sections were washed in TBS, incubated fa 1 hr in vehiGe containing biotinylated horse anti-mouse or goat anti-rabbit antibody (as per manufacturer, Vector Labs, Burtingame, CA.), washed in TBS, and then incubated for 1 hr in TBS containing ABCfiorseradish peroxidase reagent (Vector Labs, Burlingame, CA).
After additional washes in TBS, immunolocalization products were visualized by developing sections for 3 - 5 min in 50mM Tris buffer (pH 7.6) containing 0.04%
diaminobenzdine (DAB) and 0.003°~6 HzOZ. Sections were subsequently washed in the Tris buffer, mounted onto slides and dehydrated and coverslipped using OPX (Fluka, Ronkokoma, N.Y.).
Antibodies AT-8:
Used at 1:1,000 (200nglml), mouse monoclonal which recognizes ser 202 and thr of human phosphoryfated tau. (lnnogenetics, Inc. Zwij+ndrecht (Belgium)) PHF-13:
Used at 1: 20,000, mouse monoGonal which recognizes ser 398 and thr 404 of human phosphorylated tau. (Gift from V. t.ee, University of Pennsylvania) anti-TAU:
Used at 1:7,000, rabbit polytonal which recognizes total tau. (Accurate Chemical and Scientfic Corp Westbury, N.Y.).
SMI 34:
Used at 1:1000, mouse monoclonal which recognizes phosphorylated neurofilament.H (Sternberger MonoGonals, Inc., Lutherville MD) Brains from four month old transgenic and wild type mice were compared for the presence of tau and neurofllament phosphoepitopes by immunohistochemistry. AT-8 and PHF-13, monoGonal antibodies which recognize phosphorylated Ser-202 and Thr-205, and Ser-396,404, respectively, labeled neurons in amygdaia (Figs. 2 and 4, respectively), thalamuslhypothalamus and cortex adjacent to external capsule (not shown) of transgenic animals but not in corresponding regions of wild-type animals (Figs. 3 and 5).
In addition, staining for total tau revealed numerous cell bodies in p25 transgenic animals (Fig. 6) while mostly axons and very few cell bodies were labeled in wild type mice (Fig. 7).
A monoclonal antibody (SM134) recognizing phosphorylated neurofilament H also showed increased immunostaining in these three brain regions and spinal cord of transgenic mice (amygdala is depicted in Fig. 8), but not in wild type (Fig. 9). All three of these markers are known to be increased in Alzheimer brain relative to age-matched control.
In Alzheimer's brain, pathological changes in neurons containing altered tau proteins have classically been identified using silver-based staining methods. We found that, in the transgenic mice of this invention, neurons in the same three brain regions described above and spinal cord show positive labelling using the modified Bielschowsky silver stain (amygdala, Fig. 10). This staining was once again absent in wild-type control animals (Fig.
11 ). We also detected increases in silver staining and phosphorylated neurofilament H in obviously enlarged axons in the spinal cord of transgenic mice (Figs. 12 and 13, respectively), while in wild type mice, axons were of the expected diameter and neurofilament staining was normal (Fig. 14).
With regard to AT-8 immunoreactivity, most labelled neurons in the amygdala exhibited well-defined, densely staining soma, often with a swollen, dystrophic hillock and contorted axon (Fig. 2). Less commonly, diffuse labelling of unidentified cells was seen, and occasionally cells having astroglial or microglial morphology were labelled.
In cortex adjacent to external capsule, the majority of AT-8 staining was found in intensely-labelled neuronal cell bodies, often accompanied by axons when present in the plane of the section.
Thalamic/hypothalamic staining was more diverse, including both neuronal staining as seen in other sections.
Histologic examination of brain and spinal cord from p25 Tg mice revealed changes in neurons and axons of brain or spinal cord (n = 19) but not in these tissues from 10 age-matched, wild-type controls. Axonal changes were most pronounced in the spinal cord (cervical and thoracic) and consisted of marked dilation of axoplasm to diameters of 20 to 50 Vim. Dilated axons were filled with both silver staining and phosphorylated neurofilament H
(Figs. 12, 13). A given cross section of affected cord generally contained between 10 and 100 overtly dilated axons distributed among all funiculi of white matter. Luxol fast blue staining illustrated dissolution of the internal portion of myelin sheath of affected axons (not shown).
OTHER PUBLICATIONS
(45) Baumann, K., E. M. Mandelkow, et al. (1993). "Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 ° FEBS Letters 336(3): 417-24.
(32) Bazan, J. F. (1996). "Helical fold prediction for the cyclin box."
Proteins 24(1 ):
1-17.
(9) Biernat, J., N. Gustke, et al. (1993). "Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubuie binding." Neuron 11 (1 ): 153-63.
(6) Biernat, J., E. M. Mandelkow, et al. (1992). "The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region." EMBO Journal 11 (4): 1593-7.
(17) Billingsley, M. L. and R. L. Kincaid (1997). "Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration." Biochemical Journal 323(Pt 3): 577-91.
(7) Bramblett, G. T., M. Goedert, et al. (1993). "Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding." Neuron 10(6): 1089-99.
(31 ) Brown, N.R., M.E. Noble, et al. {1995) "The crystal structure of cyclin A."
Structure 3(11 ): 1235-47.
(36) Chae, T., Y. T. Kwon, et al. (1997). "Mice lacking p35, a neuronal specific activator of CdkS, display cortical lamination defects, seizures, and adult lethality." Neuron 18(1 ): 29-42.
(54) Donehower, L. A., M. Harvey, et al. (1992). "Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours:' Nature 356(6366): 215-21.
(55) Forss-Petter, S., P. E. Danielson, et al. (1990). "Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control "
Neuron 5(2): 187-97.
Franklin and Paxinos, "The Mouse Brain in Stereotaxic Coordinates", 1997.
(11) Goedert, M., R. Jakes et al. (1996) "Assenbly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans." Nature 383:550-553.
(2) Goedert, M. (1997). "The Neurofibrillary Pathology of Alzheimer's Disease."
The Neuroscientist 3(2): 131-141.
(3) Goedert, M., R. A. Crowther, et al. (1998). "Tau mutations cause frontotemporal dementias." Neuron 21 (5): 955-958.
Throughout the speafication, s number of pubkcations are cited. A complete listing of the p~a~~ ~ter in the speafi~lion.
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder characterized by loss of cognitive function. The primary neuropathologicai lesions in AD are amyloid plaques and neurofibrillary tangles (NFTs). Amyloid plaques are composed primarily of amyloid beta (Ab) peptides, varying in length from 39-42 amino acids, which are derived from amyloid precursor protein (APP) (reviewed in 1 ). NFTs are composed of the microtubule binding protein tau that is hyperphosphorylated at epitopes which exist in a predominantly unphosphorylated state in disease-free brain (2-4). The respective roles that these lesions play in the neuronal loss and dementia observed in patients with AD remain controversial.
The precise mechanism of NFT formation is not Gear but work from many laboratories suggests that hyperphosphoryiation of tau may be an important event. The paired helical filament (PHF) is the fundamental unit of the NFT.
Hyperphosporylation of tau at serine or threonine residues followed by proline (SP or TP), epitopes which are concentrated at the amino and carboxy termini of tau, results in loss of affinity for microtubules, and a presumed concomittant increase in the concentration of cytoplasmic tau (5-8). However, phosphoryiation of tau at serine 262, which is not followed by proline, can also reduce the affinity of tau for microtubules (9). in vitro experiments with purified tau show that in the presence of endogenous rations (e.g., mRNA, heparin sulfate proteoglycan), tau polymerizes to form structures indistinguishable from the PHF seen in AD brain (10,11). The ration-dependent formation of PHF in vitro is independent of the phosphorylation state of tau, suggesting that the key permissive event in initiating PHF formation may be an increase in the cytoplasmic concentration of tau. In support of this hypothesis, recent evidence (12-14) indicates that the mutations in the tau gene associated with susceptibility to a form of inherited l'SERS~DOC~LA:1932~LPRFS'.2Q9X01! DOC ~ I:7763 i PCIOI~:.RFS (NEW PATEN11 dementia called frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), reduce the affinity of tau for microtubules (15). Therefore these mutations, like hyperphosphorylation, may result in an increase in cytoplasmic tau concentrations. In the presence of endogenous cations, this increase is presumed to permit PHF
formation followed by NFT assembly and, ultimately, neuronal death.
As with other phosphoproteins, the phosphorylation state of tau is the sum of protein kinase and protein phosphatase activity. Thus hyperphosphorylation of tau in AD may be due to an increase in kinase activity or a decrease in phosphatase activity. While many protein kinases phosphorylate tau at AD-relevant epitopes in vitro (reviewed in 16,17), only two have been co-purified with microtubules from mammalian brain, GSK3b and cdk5 (18).
To our knowledge, only these two kinases will phosphorylate tau when transfected heterologously into mammalian cells (19,24). We chose to focus on cdk5 vs. GSK3b as the latter plays a role in energy metabolism and is expressed in an active form in all cells, while cdk5 is only active in neurons (vide infra).
The kinase cdk5 is a member of the cyclin-dependent protein kinase family and is expressed in nearly all cells (reviewed in 25,26). Unlike other members of the cdk family, there is no known cyclin which activates cdk5. Rather, the positive allosteric regulators of cdk5 are p35 (27), amino terminal proteolytic fragments of p35, e.g, p25, p23 or p21 (28,29) and p39 (30). These proteins share minimal amino acid sequence homology to cyclins (27-29) but computer modeling and biochemical experiments suggests that the mechanism of activation of cdk5 by p25/35 may be similar to that of cyclin A activation of cdk2 (31-33). The protein p25/35 is expressed predominantly in neurons implying that most cdk5 activity is concentrated in neuronal structures (27,28). The protein p35 has a relatively short half life within cells and is rapidly ubiquitinated, suggesting tight regulation of cdk5 activity in neurons (34). The kinase cdk5 plays a pivotal role in neuronal development as evidenced by the abnormal corticogenesis and perinatal lethality of cdk5 knockout mice (35) and the disturbances in neuronal migration and early death in p35 knock-out mice (36).
In developmental studies in rodents, the peak catalytic activity of cdk5 occurs at E11 or 12, lending further support for the role of cdk5 in neurogenesis (37,38).
Furthermore, in primary cultured neurons, cdk5/p35 is localized to growth cones suggesting a role in neurite outgrowth (39). Recently, evidence of signaling pathways which may modulate cdk5 activity have emerged. For example, it has been demonstrated that cdk5/p35 interacts with Rac and modulates PAK activity (40), and that laminin-enhanced outgrowth of cerebellar neurons is disrupted by suppression of p35 expression (41 ). A few substrates for cdk5 have been identified and are consistent with the presumed role in neurite outgrowth and plasma membrane dynamics. These include cytoskeletal proteins such as tau (42-45) and neurofilament (46-48), synaptic vesicle proteins such as synapsin and Munc-18 (49,50) and the retinoblastoma protein (51 ). Nevertheless, neither a clear picture of a signal transduction pathways) which regulates cdk5/p35 activity nor the role of both cdk5/p35 in mature brain have been elucidated.
A clear picture of the protein kinases responsible for the hyperphosphorylation of tau in AD is also lacking. However, evidence that cdk5 may a play a pathological role is accumulating. For example, in in vitro studies, cdk5 will phosphorylate up to eight different epitopes of tau, including those associated with AD and known to decrease the affinity of tau for microtubules (42-45). Additionally, heterologous co-transfection of cdk51p25 with tau into mammalian cells also results in phosphorylation of several of these epitopes (24). Finally, immunohistochemical evidence suggests that cdk5 is proximal to NFTs in AD
brain (52,53).
The development of experimental models of Alzheimer's disease that can be used to define further the underlying biochemical events involved in AD pathogenesis would be highly desirable. Such models could be employed, in one application, to screen for agents that alter the degenerative course of AD. For example, a model system of AD could be used to screen for environmental factors that induce or accelerate the pathogenesis of AD.
Alternatively, an experimental model could be used to screen for agents that inhibit, prevent, or reverse the progression of AD. Such models could be employed to develop pharmaceuticals that are effective in preventing, arresting or reversing AD. Only humans and aged non-human primates develop any of the pathological features of AD. The expense and difficulty of using primates and the length of time required for developing the AD pathology makes extensive research on such animals prohibitive. Rodents do not develop AD, even at an extreme age.
Despite various reports that certain treatments result in hyperphosphorylation of tau and/or neuronal death associated with the phosphorylation of tau, there is a need in the art for transgenic non-human animals which can produce hyperphosphorylation of tau and associated neuronal death.
Based on the above, it is clear that a need exists for nonhuman cells and nonhuman animals which produce hyperphosphorylation of tau and neuronal cell death.
Thus, it is an object of the invention herein to provide methods and compositions for transferring transgenes and homologous recombination constructs into mammalian cells, especially into embryonic stem cells. It is also an object of the invention to provide transgenic non-human cells and transgenic nonhuman animals harboring transgenes resulting in the increased expression of p25, an activator of cdk5. Of further interest to the present invention are the application of such transgenic animals as in vivo systems for screening test compounds for the ability to inhibit or prevent the production of hyperphosphorylated tau and associated neuronal death. It is desirable to provide methods and systems for screening test compounds -a-for the ability to inhibit or prevent the phosphorylation of tau and associated neuronal death.
In particular, it is be desirable to base such methods and systems on inhibition of cdk51p25.
where the test compound blocks phosphorylation of tau mediated by cdk5lp25, the test compound also blocks neuror>ai death. Such methods and transgenic animals should provide a rapid, economical and suitable way for screening large numbers of test compounds.
We overexpressed human p25 in the brains of mice to determine if an inaease in cdk5 activity would result in the hyperphosphorylation of tau at AD-relevant epitopes, and if this hyperphosphorylation would lead to neuronal death. In the brains of p25 transgenic mice, both tau and neurofilament are hyperphosphorytated, and many silver-positive neurons with tangle-like inGusions are present. The silver-positive neurons suggest ongoing neuronal death. These results demonstrate that overexpression of an activator of cdk5 is sufficient to produce tau and neurofilament phosphorylation and silver-positive neurons which are very similar to those seen in AD. The p25 transgenic mouse may serve as a model for the neurofibrillary pathology and neuronal death seen in AD.
Summary of the Invention In one embodiment. the present invention is directed to a purfied and isolated recombinant poiynuueoa0e comprising a neuron speafic enotase promoter operably linked to a p25 encoding sequence.
In a preferred embodiment, the present mention is directed to recombinant DNA
wherein said sequence encoding said p25 protein s genomic DNA.
In another preferred embodiment, the present invention is directed to recombinant DNA wherein said sequence encoding said p25 protein ~s cDNA.
In still another preferred embodiment, the present invention is directed to recombinant DNA wherein said sequence is that of SEA ID NO: a In yet another embodiment, the present invention is directed to a vector comprising recombinant DNA according to the present invention.
In another embodiment, the present invention is directed to eukaryotic cell comprising recombinant ONA according to the present invention.
In another embodiment, the present invention is directed to a transgenic non-human animal, or progeny thereof, whose germ cells and somatic cells express recombinant DNA
according to the present invention.
In a preferred embodiment, the present invention is directed to a transgenic non-human animal, or progeny thereof, which is a mouse.
In a further embodiment, the present invention is directed to a method for treating an animal having a disease characterized by the expression of a p25 fragment of a human cdKS
gene comprising administering a therapeutically effective amount of an inhibitor of said p25 fragment.
In another embodiment, the present invention is directed to a method for determining the ability of a compound to inhibit the expression of a p25 protein comprising the steps of:
a. creating a transgenic non-human animal by stably incorporating into the embryonic stem cells of said animal a recombinant polynucleotide composing a neuron-speicific enolase promoter operably linked to an encoding sequence for p25;
b. growing said embryonic stem cells into a mature transgenic non-human animal;
c. administering to said transgenic non-human animal the compound of interest;
d. measuring the inhibition of said p25 protein by said compound.
In still another embodiment the present invention is directed to a method for generating data to determining the ability of a compound to inhibit the expression of a p25 protein comprising the steps of:
a. creating a transgenic non-human animal by stably incorporating into the embryonic stem cells of said animal a recombinant polynucleotide comprising a neuron-speicific enolase promoter operably linked to an encoding sequence for p25;
b. growing said embryonic stem cells into a mature transgenic non-human animal;
c. administering to said transgenic non-human animal the compound of interest;
d. measuring the inhibition of said p25 protein by said compound;
e. using the data derived from said inhibition to synthesize compounds capable of inhibiting said p25 protein.
Figure 1A. Western blots of the amygdala (1), thalamus (2) and cortex (3) from 3 wild type mice were probed with an antibody specific for p25 and p35/39 (generous gift of L.-H.
Tsai, Harvard Medical School Cambridge, MA).
Figure 1 B. Western blots of the amygdala (1 ), thalamus (2) and cortex (3) from 3 p25 transgenic mice were probed with the same antibody as in FIG 1A.
Expression of the transgene, p25, is apparent in the transgenic but not wild type mice.
Figure 2 displays a four month old transgenic mouse brain imunopositive for AT-8 (a commercially available antibody which specifically recgnoizes phopho-serine 202/205 of tau) specific in the rostral portion of the amygdala. Neuronal cell bodies with accompanying axons (arrows) are positive. Several dark-brown positive cells are seen in this field.
Figure 3 shows a four month old wild-type mouse brain minimally positive for AT-8 in the rostra) portion of the amygdala. A cell body exhibits non-specific positivity (arrow) due to the secondary antibody.
Figure 4 shows a four month old transgenic mouse brain demonstrating PHF-13 (an antibody which recognizes phospho-serine 396/404 of tau; (gift from Dr. V.
Lee, U. of Pennsylvania) immunopositivity in the rostra) portion of the amygdala.
Neuronal cell body with a thickened axon (arrow) is positive. Positive neuronal cell body (arrow head) with possible swollen/atrophied axon.
Figure 5 shows a four month old wild-type mouse brain minimally positive for in the rostra) portion of the amygdala. Cell bodies exhibit non-specific positivity (arrows) due to the secondary antibody.
Figure 6 shows a four month old transgenic mouse brain immunopositive for total tau (an antibody which recongnizes total tau commercially available from Accurate Chemical and Scientific Corp Westbury, N.Y.) in several cell bodies of the rostra) amygdala (examples marked by arrows).
Figure 7 shows a four month old wild-type mouse brain immunopositive for tau in axons (arrow heads) of the rostra) amygdala.
Figure 8 shows a four month old transgenic mouse brain reacted with SMI-34 (a commercially available antibody which recognizes phosphorylated neurofilament H protein).
Positive cells (arrows) are seen in the rostra) amygdala.
Figure 9 shows minimal SMI-34 axonal positivity in the rostra) amygdala of a four month old wild-type mouse brain.
Figure 10 shows silver-positive (an indication of disrupted cytoskeleton and neuronal cell death) cell bodies (arrows) in the rostra) amygdala of a four month old transgenic mouse brain.
Figure 11 shows minimal silver positivity of axons in the rostra) amygdala of a four month old wild type mouse.
Figure 12 shows several dilated axons (arrows) that exhibit silver positivity in the spinal cord of a five month old transgenic mouse.
Figure 13 shows several dilated axons (arrows) that exhibit SMI-34 positivity in the spinal cord of a five month old transgenic mouse.
Figure 14 shows that normal axons in the spinal cord of a six month old wild-type mouse are negative for SMI-34.
Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, nucleic acid chemistry and hybridization, biochemistry, histology and immunocytochemistry described below are those well known and commonly described in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, cell culture, transgene incorporation, Western blotting, immunocytochemistry and histological techniques such as silver staining. The techniques and procedures are generally performed according to conventional methods in the art and various general refererxes which are provided throughout this specification. The procedures therein are well known in the art and are provided for the convenience of the reader.
In accordance with the foregoing objects, in one aspect of the invention are provided nonhuman animals harboring at least one copy of a transgene comprising a polynucleotide sequence that encodes a heterologous protein operably linked to regulatory elements that are capable of expressing the heterologous protein in the transgenic nonhuman animal. Said heterologous polypeptide is a truncated portion of the p35 cyclin dependent kinase 5 (cdk5) regulatory protein (27,28). The truncated heterologous polypeptide has the first 98 N-terminal amino acids removed and has a molecular weight of approximately 25,000 daltons. This novel polypeptide will be referred to as p25. Typically, the nonhuman transgenic animal is a mouse and the heterologous gene is the human p25 sequence. Transgenes are typically cDNR
sequences that have been operably linked to cis-acting regulatory sequences that direct expression in the host transgenic mammal in cell-type specific manner, typically in neurons.
Typically, the transgene will be incorporated into the host chromosomes in random, non-targeted fashion. The invention further provides that the nonhuman, transgenic animal harboring at least one copy of the heterologous p25 sequence transgene or gene targeting vector of the invention either non-homologously or homologously integrated into the chromosomal location express the p25 truncated polypeptide. Transgenic animals are typically produced by introduction of a transgene by microinjection into pronuGei of one-cell embryos or a targeting vector into the host by electroporation, lipofection, or viral transfection of embryonic stem (ES) cells. The transgenic animals that express the p25 polypeptide are suitable for use as models of disease and screening of potential therapeutic compounds including small molecules, proteins and polynucleotides. The invention also provides nonhuman or human cell lines to be derived by transformation of established cell lines or primary cell lines established directly from the nonhuman transgenic animal, for example neurons. It is obvious that the transgenic nonhuman animal can have additional genetic modifications by transgenic art or through traditional matings with other transgenic or naturally occurring animals to produce novel animals that serve as alternative disease models, drug saeens or other applications. This includes the inactivation of the murine endogenous p35 gene through gene targeting in ES cells and resultant murine p35-deficient mice that becomes the preferred host for expression of the human p25 heterologous polypeptide.
Such _8_ heterologous transgenes may be integrated in nonhomologous chromosomal locations in the transgenic animal, typically derived by pronuclear injection or may be integrated by gene targeting in ES cells by methods to inactivate the murine p35 gene and add linked sequences to direct expression of the heterologous human p25 sequences.
In general, the invention encompasses methods for the generation and characterization of transgenic animals that express the human p25 polypeptide, a proteolytic fragment of p35, both of which are an allosteric activators of cyclin dependent kinase 5 (cdk5).
The transgenic animals express this human protein in the presence of the endogenous homologue. The techniques and procedures are performed according to established protocols that are generally considered to be routine methods in the art and references are provided within this specification. The protein kinase cdk5 when associated with an allosteric activator, e.g., p35 or p25 is reported in the literature to phosphorylate tau in vitro and in whole cells (see Background of the Invention). The transgenic mice thus produced establish the role of the human p25 in the formation of hyperphosphorylated tau in neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, amyelolateral sclerosis, Huntington's chorea, stroke, traumatic brain injury, Pick's disease, neuraxonal dystrophy, multiple sclerosis, motor neuron disease, and spinocerebellar degeneration and other neurodegenerative diseases. It is apparent that the preparation of other transgenic animals that express the human p25 protein is easily accomplished including rats, hamsters, guinea pigs and rabbits. The transgenic animals that express the human p25 protein can be monitored for the level of expression and tau phosphorylation. It will be appreciated that under different conditions the level of expression and degree of tau phosphorylation will be inhibited in such an animal model. In particular, the screening of therapeutic agents that inhibit the activity of the human p25 protein will be greatly facilitated in animal models. It is apparent that the development of cell lines from the affected transgenic animals, (e.g., neurons) will improve the throughput in which biochemical and pharmacological analysis of the human p25 protein can be assessed.
Particularly preferred animal models for p25 overexpression are transgenic anmals which express p25 as described above. Such transgenic animals, particularly transgenic mice according to this invention, produce high quantities of p25 and hyperphosphorylated tau and neuronal death which may be detected according to the methods of the present invention.
In accordance to this invention particular, the overexpression of p25 will be equal to or greater than endogenous p25 expression in such animals. Further, this level of p25 overexpression results in tau hyperphosphorylation which is minimal in wild type animals.
With such elevated levels of p25, monitoring of hyperphosphorylation of tau and neuronal death is greatly facilitated. In particular, screening for compounds and other therapies for inhibiting tau _g_ phosphorylation are greatly simplified in animals overexpressing p25 according to this invention.
Agents are administered to test animals, such as test mice, which are transgenic and which overexpress p25. Particular techniques for producing transgenic mice which overexpress p25 are described below. It will be appreciated that the preparation of other transgenic animals overexpressing p25 may easily be accomplished, including rats, hamsters, guinea pigs, rabbits, and the like. In light of this disclosure, the effect of test compounds on the hyperphosphorylation of tau in the test animals may be measured in various specimens from the test animals.
The effect of test agents on hyperphosphorylation of tau may be measured in various specimens from the test animals. In all cases, it will be necessary to obtain a control value which is characteristic of the level of tau phosphorylation and neuronal death in the test animal in the absence of the test compound(s). In cases where the animal is sacrificed, it will be necessary to base such control values on an average or a typical value from other test animals which have been transgenically modified to overexpress p25 but which have not received the administration of any test compounds or any other substances expected to affect the level of tau phosphorylation or neuronal death. Once such control level is determined, test compounds can be administered to additonal test animals, where deviation from the average control value indicates that the test compound had an effect on the tau phosphorylation or neuronal death in the animal. Test substances considered positive, i.e., likely to be beneficial in the treament of AD or other neurodegenerative diseases, will be those which are able to reduce the level of tau phosphorylation or neuronal death preferably by at least 20% and most preferably by 80%. In addition there may be paired helical or straight filament formation in transgenic animals which overexpress p25 and display tau hyperphosphorylation.
In these cases, test compounds can be administered to test animals and the reduction of filament formation monitored as a result of exposure to the compound. In addition, there may be behavioral alterations in the transgenic animals which overexpress p25 and display tau hyperphosphorylation. In these cases it will be necessary to obtain a control value from live animals performing a behavioral task (e.g., the measurement of locomotor activity) in the test animal in the absence of test compound(s). Such a control will also be determined in non-transgenic, wild type mice. The difference between the wild type and transgenic mice will serve as the outcome measure for the effects of compounds. Once such control levels are determined, test compounds can be administered to additional test animals, where reduction in or reversal of the difference between the wild type and transgenic mice indicates that test compound has an effect on the behavioral test being measured. Test substances considered positive, i.e., likely to be beneficial in the treament of AD or other neurodegenerative diseases, preferably will be those which are able to reverse or, substantially reverse, or favorably modify the behavioral abnormality in the transgenic animal to the level found in wild type mice.
Test agents will be defined as any small molecule, protein, polysaccharides, deoxy or r~ortxrcleotides, or any combination !hereof that when added to the cell culture a animal will not adversely interfere with the colt a animal viability. Agents that alter the level of human p25 express'ron and tau phosphorylation will be considered as candidates for further evaluation as potential therapeutics. The test compound will typically be administered to transgenic animals at a dosage of from 1 ngJkg to 100mgltcg, usually from 1 Ouglkg to 32 mgJkg.
Test compounds which are able to inhibit phosphorylation of tau are considered as candidates for fuller determinations of the ability to block tau phosphorylation in animals and humans. Inhibition of tau phosphorylation indicates that cdk5lp25 activity has been at least partly blocked, reducing the amount of cdk5lp25 available to phosphorylate tau.
The present invention further comprises pharmaceutical compositions incorporating a compound selected by the above-described method and including a pharmaceutically acceptable carrier. Such pharmaceutical compositions should contain a therapeutic or prophylactic amount of at least one compound identified by the method of the present invention. The pharmaceutically acceptable carrier can be any compatible, non-toxic substance suitable to deliver the compound or compounds to an intended host.
Sterile water, alcohol, fats, waxes and inert solids may be used as the carrier.
Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like may also be incorporated into the pham~aceutical compositions. Preparation of pharmaceutical compositions incorporating active agents is well described in the medical and scientific literature. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16°' Ed., 1 ssz.
The pharmaceutical compositions just described are suitable for systemic administration to the host, including both parenteral, topical, and oral administration. The pharmaceutical compositions may be administered parenterally, i.e., subcutaneously, intramuscularly or intravenously. Thus, the present invention provides compositions for administration to a host where the compositions comprise a pharmaceutically acceptable solution of the identified compound in an acceptable carrier, as described above.
Commercial Research and Screening Uses Non-human animals comprising transgenes which encode p25 can be used commercially to screen for agents having the effect of preventing or reducing the phosptmrylation of tau and neuronal death. Such agents can be developed as pharmaceuticals for treating hyperphosphorylation of tau and AD amongst other neurodegenerative diseases. For example, the p53 knockout mice of Donehower et al. (54) have found wide acceptance as commercial prouducts for carcinogen screening and the like.
The transgenic animals of the present invention exhibit abnormal tau phosphorylation and can be used for pharmaceutical screening and as disease models for neurodegenerative diseases and cdk5/p25 and tau biochemistry. Such animals have many uses including but not limited to identifying compounds that affect tau hyperphosphorylation; in one variation, the agents are thereby identified as candidate pharmaceutical agents. The transgenic animals can also be used to develop agents that modulate cdk5 or p25 expression and or stability;
such agents can serve as therapeutic agents to treat neurodenerative diseases. The p25 overexpressing mice of the invention can also serve as disease models for investigating tau-related pathologies (e.g., AD, Pick's disease, Parkinson's disease, frontal temporal lobe dementia associated with chromosome 17, stroke, traumatic brain injury, mild cognitive impairment and the like). Such transgenic animals can be commercially marketed to researchers, among other uses.
Having described the invention in general terms, reference is now made to specific examples. It is to be understood that these examples are not meant to limit the present invention, the scope of which is to be determined by the appended claims.
The plasmid pNSE-p25 (rat neuron specific enolase promoter, human p25 transgene) contains DNA from 4 different sources: the rat neuron specific enolase promoter; the human cDNA for the p25 catalytic fragment of the p35 protein; the SV40 polyadenylation signal sequence and a commercially available plasmid vector. The transgene is isolated by BamH1 restriction enzyme digestion of pNSE-p25. This restriction digest releases the NSE-p25 transgene (3212 bp) from the plasmid cloning vector pSP72 (2462 bp) (Promega, Madison, WI). The rat Neuron Specific Enolase (NSE) promoter sequence is 1826 by (SEQ
ID NO: 1 ) and has been demonstrated to efficiently express DNA coding sequences in neurons of transgenic mice (55). The coding region for the human p25 sequence is 633 bp.
(SEQ ID NO:
2). The 3-prime untranslated and SV40 polyadenylation sequence are 688 by (SEQ
ID NO:
3). The microinjected NSE-p25 transgene is 3212 by (SEQ ID NO: 4). Enzymatic reactions of recombinant DNA, including ligations, restriction endonuclease digestions, DNA
synthesis reactions, single strand fill-in reactions, and bacterial transformations performed are well established procedures as described by Sambrook, J., Fritsch, E.F. and Maniatis, T.
Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Press, New York, 1989.
The SV 40 polyadenylation sequence (SEQ ID NO: 3) was cloned into the commercially available plasmid pSP72 (SEQ ID NO: 5) at Xba1 and BstX1 sites.
This plasmid, designated pSP-SVpA, served as the backbone vector for the construction of the NSE-p25 transgene plasmid. The cDNA for the human p25 catalytic fragment was derived using polymerase chain reaction (PCR). The human p35 full length cDNA was used as the template for amplification of the p25 insert. We received the p35 template DNA
from Dr. David Auperin of Pfizer; the human p35 sequence was cloned into the EcoR1 site of the pFastBacl, baculoviral expression vector (Gibco-BRL, Gaithersburg, MD). The PCR primers were designed to have Not1 restriction sites outside the coding sequence to facilitate tsansgene construction. The forward primer also introduced a new ATG start codon adjacent to the GCC
(Ala codon at position 99 of the human p35 sequence). The primers (submitted in 5-prime to 3-prime orientation) were p25-forward:
GCGGCCGCATGGCCCAGCCCCCACCGGCCCAGCCGCCTGCA
(SEO ID NO: 6) and p25-reverse:
CTCCTCCTAGGCCTGGAATCGGTGAGGCGGCCGC (SEQ ID NO: 7). The ATG is introduced start codon, the TGA is the stop codon and the GCGGCCGC are the Not1 restriction sites added to the PCR primers. The resulting PCR product is 648 by containing the entire 633 by human p25 cDNA sequence with engineered ATG start site (SEQ
ID NO: 2) and an additional 15 by from addition of the Not 1 cloning sites. The 648 by fragment was subcloned into the pCR2.1 (Invitrogen, Carlsbad, CA) vector for verification of sequence prior to use as insert in the final transgene. The confirmed 648 by Not 1 fragment was ligated into the Not 1 restriction site of pSP-SVpA producing the plasmid pSP-SVpA:p25. The rat Neuron Specific Enolase (NSE) promoter was isolated from the plasmid pNSE-IacZ
obtained from Dr.
J.G. Sutcliffe of the Research Institute of Scripps Clinic (LaJolla, CA). The rat NSE promoter sequence (SEQ ID NO: 1 ) was isolated by EcoR1 and Hind III restriction digestion of the pNSE-IacZ plasmid. The 1.8 kb fragment was extracted by agarose gel electrophoresis and purified. The 5-prime single strand overhangs generated by the restriction enzymes were filled by Klenow reaction to produce the rat NSE promoter fragment with double stranded blunt ends. The 1826 by rat NSE blunt end promoter fragment was blunt end ligated into the Sma 1 restriction site of pSP-SVpA:p25. The correct orientation of the rat NSE
promoter within the pSP-SVpA:p25 was verified by double restriction digests of BamH1 and Xhol.
Plasmids with the correct orientation were assigned the designation as pNSE-p25. The entire sequence of the 3212 by NSE-p25 transgene (SEQ ID NO: 4) was analyzed and verified by automated sequencing on ABI 373 sequences (Foster City, CA) using the standard dye-terminator chemistry protocol outlined by ABI. All plasmids were grown in DHSalpha bacterial cells (Gibco BRL Gaithersburg MD).
Production of transgenic mice overexpressing human p25.
The 3212 by NSE-p25 transgene DNA fragment was excised from the pNSE-p25 plasmid by BamH1 restriction endonuclease reaction. The 3.2 kbp fragment was isolated by electroelution (50V, 3 hrs) after electrophoresis in 1 % agarose gel (FMC
Bioproducts, Rockland ME). The fragment was further purified by on a Schleicher and Schuell (Keene, NH) Elutip-d column following protocols established by the manufacturer for DNA
purification prior to murine embryo microinjection.
Production of transgenic mice by pronuclear microinjection was carried out by published procedures as outlined in Hogan, B. et al Manipulating the Mouse Embryo: A
Laboratory Manual 2nd edition, Cold Spring Harbor Laboratories, New York, 1994.
Pronuclear stage embryos from F1 females mice of the strain FVB/N (Charles River Labs, Wilmington, MA) were obtained after superovulation with 5 international units (IU) of follicle stimulating hormone from pregnant mare serum (Sigma St Louis, Mo.) and 2.5 LU.
human chorionic gonadotropin (Sigma). The actual microinjection procedure was performed as described by Wagner, T. et al. (56) except that the embryos were transferred immediately to pseudopregnant CD-1 recipient females (Charles River Laboratories, Wilmington, MA) for development of embryos to term. Mice resulting from the reimplantation events were tested for the presence of the NSE-p25 transgene by PCR analysis of genomic DNA isolated from tail biopsies at 3 weeks of age. The mice that demonstrated positive for the presence of the NSE-p25 transgene were mated with wild type FVB/N mice (Charles River Laboratories, Wilmington, MA) of the opposite sex. Offspring of these matings were tested for germline transmission by PCR analysis or Southern blot analysis of genomic DNA isolated from tail biopsies at 3 weeks of age. Transgenic lines were produced from 7 founder transgenic mice and were maintained by breeding to wild type FVB/N mice and PCR genotyping for the presence of the NSE-p25 transgene.
The experiments described below were done in mice heterozygous for the inserted transgene. These mice were derived by breeding mice positive for the transgene insert with FVB/N wild-type animals and screening offspring by PCR for presence of the NSE-p25 transgene sequences.
Detection of overexpression of p25 protein.
Western Blot Whole brains from 1 or 4 month old transgenic (Tg) and wild type (wt) mice were removed and snap frozen in liquid nitrogen. Amygdala, thalamus and cortex were dissected and homogenized in 1 ml of lysis buffer (as described in 37). The samples were boiled for 10 minutes and then centrifuged at 13,000 rpm. Protein concentrations of the resulting supernatants were determined by the Pierce BCA method (BCA micro protein assay, catalog #23225, Pierce, Rockford ILL). Ten micrograms of each sample were electrophoresed on an SDS polyacrylamide gel (57) and transferred to ProBlott protein paper for western blot analysis [Western blotting protocols, ECL detection, Amersham Life Science Arlington Heights, ILL (1995)]. Non specific sites were blocked by incubating the blots in 5% nonfat .14-milk in tris-buffered saline (20mM Tris Base, 127 mM NACI, 3.8 mM HCI pH 7.6, Sigma) included 0.1 % tween-20 ITBS~T). Primary ant~odies were diluted in 5% nonfat milklTBS-T.
The blots were pieced in the diluted antibody adutions and rotated fa 1 hr at 23°C. The western blots were then washed fa 30 min in TSS-T. Secondary horseradish peroxidase linked antibodies were diluted in 5% nonfat mi1k1T8S~T. The blots were incubated with the secondary ant~Ody solution and rotated for 45 min at 23°C. The blots were then washed for 30 min in TBS-T. Equal volumes of Amersham's ECL developing solutions A and 8 were moved together. The Western blots were inwbated fa 1 min in the devebping solution. The blots were wrapped in Saran ~ wrap and then exposed to imaging film (Kodak Rochester N.Y.
X-OMAT AR"', anfstog X1651454).
Western blots of the amygdala (1), thalamus (2) and cortex (3) from 3 mice were probed with an antibody specific fa p25 and p35139 (gift of L.-H. Tsai, Harvard Medical School, Figure 1A). While detection of p35139 is apparent, no p25 is detected in wild type mice. When the same analysis is performed in the transgenic mice (Figure 1 t3), robust expression of p25 in addition to the constitutive expression of p35 is detected. These results confirm that expression of the transgene is robust in the p25 transgenic animals.
Silver Stain 8 SMI 34 Immunohistochemistry Tissues collected from scheduled sacrifice mice were perfusion-fixed in situ with 10°k neutral-buffered formalin or 4% paraformaldehyde, whereas tissues collected from mice found dead were immersion faced in formalin. Following fixation, trimmed tissues were dehydrated through graded alcohols and embedded in paraffin. Standard cross sections of brain were identfied by analogy to figures in The Mouse Brain in Sterevtaxic Coordinates (Franklin and Paxinos, 1997). Paraffin sections (8pm thick) were stained with mod~ed Bielschowsky silver stain and, immunohistochemically, with an antibody directed against phosphorylated neurofilament (SMI 34, commercially availaable from Stemberger Monodonals, Inc Lutherville, MD).
Immunohistochemistry For immunohistochemical studies, transgenic and wild type mice were deeply anesthetized with sodium pentobarbital (ti0 mg/kg, i.p.) and perfused through the ascending aorta with 20 ml of 0.1 M NaPO, containing 0.9% NaCI (PBS, 7.4) followed by 30 ml of fucative containing 4% paraformaldehyde in 0.1 M NaPO, (PB, 7.4) buffer. The brains were removed, cryoprotected for 48 hr in PBS containing 20% suaose, frozen in a bed of pulverized dry ice, and then cut into 35 micron secfrons on a sliding microtome. Consecutive 1 in 18 series of sections were collected in 0.1 M PB and processed for immunohistochemistry as described below.
For immunohistochemistry, sections were inarbated for 1 hr in 50 mM Tris buffer, ph 7.4 containing 0.9% NaCI (TBS) and 0.1 % Trilon-X-100'x. The sections were then washed in TBS and inabated for 1 hr in antibody vehicle (4% goat or horse serum, 0.1 %
Trwort-X-100~" in TBS). After additional washes in T13S, sections were incubated overnight at 4°C in vehicle containing the primary antibody.
Fdlowing overnight incubation in the primary antibody, sections were washed in TBS, incubated fa 1 hr in vehiGe containing biotinylated horse anti-mouse or goat anti-rabbit antibody (as per manufacturer, Vector Labs, Burtingame, CA.), washed in TBS, and then incubated for 1 hr in TBS containing ABCfiorseradish peroxidase reagent (Vector Labs, Burlingame, CA).
After additional washes in TBS, immunolocalization products were visualized by developing sections for 3 - 5 min in 50mM Tris buffer (pH 7.6) containing 0.04%
diaminobenzdine (DAB) and 0.003°~6 HzOZ. Sections were subsequently washed in the Tris buffer, mounted onto slides and dehydrated and coverslipped using OPX (Fluka, Ronkokoma, N.Y.).
Antibodies AT-8:
Used at 1:1,000 (200nglml), mouse monoclonal which recognizes ser 202 and thr of human phosphoryfated tau. (lnnogenetics, Inc. Zwij+ndrecht (Belgium)) PHF-13:
Used at 1: 20,000, mouse monoGonal which recognizes ser 398 and thr 404 of human phosphorylated tau. (Gift from V. t.ee, University of Pennsylvania) anti-TAU:
Used at 1:7,000, rabbit polytonal which recognizes total tau. (Accurate Chemical and Scientfic Corp Westbury, N.Y.).
SMI 34:
Used at 1:1000, mouse monoclonal which recognizes phosphorylated neurofilament.H (Sternberger MonoGonals, Inc., Lutherville MD) Brains from four month old transgenic and wild type mice were compared for the presence of tau and neurofllament phosphoepitopes by immunohistochemistry. AT-8 and PHF-13, monoGonal antibodies which recognize phosphorylated Ser-202 and Thr-205, and Ser-396,404, respectively, labeled neurons in amygdaia (Figs. 2 and 4, respectively), thalamuslhypothalamus and cortex adjacent to external capsule (not shown) of transgenic animals but not in corresponding regions of wild-type animals (Figs. 3 and 5).
In addition, staining for total tau revealed numerous cell bodies in p25 transgenic animals (Fig. 6) while mostly axons and very few cell bodies were labeled in wild type mice (Fig. 7).
A monoclonal antibody (SM134) recognizing phosphorylated neurofilament H also showed increased immunostaining in these three brain regions and spinal cord of transgenic mice (amygdala is depicted in Fig. 8), but not in wild type (Fig. 9). All three of these markers are known to be increased in Alzheimer brain relative to age-matched control.
In Alzheimer's brain, pathological changes in neurons containing altered tau proteins have classically been identified using silver-based staining methods. We found that, in the transgenic mice of this invention, neurons in the same three brain regions described above and spinal cord show positive labelling using the modified Bielschowsky silver stain (amygdala, Fig. 10). This staining was once again absent in wild-type control animals (Fig.
11 ). We also detected increases in silver staining and phosphorylated neurofilament H in obviously enlarged axons in the spinal cord of transgenic mice (Figs. 12 and 13, respectively), while in wild type mice, axons were of the expected diameter and neurofilament staining was normal (Fig. 14).
With regard to AT-8 immunoreactivity, most labelled neurons in the amygdala exhibited well-defined, densely staining soma, often with a swollen, dystrophic hillock and contorted axon (Fig. 2). Less commonly, diffuse labelling of unidentified cells was seen, and occasionally cells having astroglial or microglial morphology were labelled.
In cortex adjacent to external capsule, the majority of AT-8 staining was found in intensely-labelled neuronal cell bodies, often accompanied by axons when present in the plane of the section.
Thalamic/hypothalamic staining was more diverse, including both neuronal staining as seen in other sections.
Histologic examination of brain and spinal cord from p25 Tg mice revealed changes in neurons and axons of brain or spinal cord (n = 19) but not in these tissues from 10 age-matched, wild-type controls. Axonal changes were most pronounced in the spinal cord (cervical and thoracic) and consisted of marked dilation of axoplasm to diameters of 20 to 50 Vim. Dilated axons were filled with both silver staining and phosphorylated neurofilament H
(Figs. 12, 13). A given cross section of affected cord generally contained between 10 and 100 overtly dilated axons distributed among all funiculi of white matter. Luxol fast blue staining illustrated dissolution of the internal portion of myelin sheath of affected axons (not shown).
OTHER PUBLICATIONS
(45) Baumann, K., E. M. Mandelkow, et al. (1993). "Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 ° FEBS Letters 336(3): 417-24.
(32) Bazan, J. F. (1996). "Helical fold prediction for the cyclin box."
Proteins 24(1 ):
1-17.
(9) Biernat, J., N. Gustke, et al. (1993). "Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubuie binding." Neuron 11 (1 ): 153-63.
(6) Biernat, J., E. M. Mandelkow, et al. (1992). "The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region." EMBO Journal 11 (4): 1593-7.
(17) Billingsley, M. L. and R. L. Kincaid (1997). "Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration." Biochemical Journal 323(Pt 3): 577-91.
(7) Bramblett, G. T., M. Goedert, et al. (1993). "Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding." Neuron 10(6): 1089-99.
(31 ) Brown, N.R., M.E. Noble, et al. {1995) "The crystal structure of cyclin A."
Structure 3(11 ): 1235-47.
(36) Chae, T., Y. T. Kwon, et al. (1997). "Mice lacking p35, a neuronal specific activator of CdkS, display cortical lamination defects, seizures, and adult lethality." Neuron 18(1 ): 29-42.
(54) Donehower, L. A., M. Harvey, et al. (1992). "Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours:' Nature 356(6366): 215-21.
(55) Forss-Petter, S., P. E. Danielson, et al. (1990). "Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control "
Neuron 5(2): 187-97.
Franklin and Paxinos, "The Mouse Brain in Stereotaxic Coordinates", 1997.
(11) Goedert, M., R. Jakes et al. (1996) "Assenbly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans." Nature 383:550-553.
(2) Goedert, M. (1997). "The Neurofibrillary Pathology of Alzheimer's Disease."
The Neuroscientist 3(2): 131-141.
(3) Goedert, M., R. A. Crowther, et al. (1998). "Tau mutations cause frontotemporal dementias." Neuron 21 (5): 955-958.
(5) Gustke, N., B. Steiner, et al. (1992). "The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs " FEBS
Letters 307(2): 199-205.
(44) Hasegawa, M., R. A. Crowther, et al. (1997). "Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans.
Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation." Journal of Biological Chemistry 272(52): 33118-24.
Hogan, B. et al. "Manipulating the Mouse Embryo: A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratories, New York, 1994.
(22) Hong, M., D. C. Chen, et al. (1997). "Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3." Journal of Biological Chemistry 272(40): 25326-32.
(15) Hong, M., V. Zhukareva, et al. (1998). "Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary FTDP-17." Science 282: 1914-1917.
(14) Hutton, M., C. L. Lendon, et al. (1998). "Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17." Nature 393(6686): 702-5.
(16) Imahori, K. and T. Uchida (1997). "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease." Journal of Biochemistry 121(2):
179-88.
(18) Ishiguro, K., M. Takamatsu et al. (1992). "Tau protein kinase t converts normal tau protein into A68-like component of paired helical filaments."
Journal of Biological Chemistry 267:10897-901.
(10) Kampers, T., P. Friedhoff, et al. (1996). "RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments." FEBS Letters 399(3): 344-9.
(57) Laemmli, U. K. (1970). "Cleavage of structural proteins during the assembly of the head of bacteriophage T4." Nature 227(259): 680-5.
(51 ) Lee, K. Y., C. C. Helbing, et al. (1997). "Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein." Journal of Biological Chemistry 272(9):
5622-6.
(28) Lew, J., Q. Q. Huang, et al. (1994). "A brain-specific activator of cyclin-dependent kinase 5." Nature 371 (6496): 423-6.
(46) Lew, J., R. J. Winkfein, et al. (1992). "Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2."
Journal of Biological Chemistry 267(36): 25922-6.
(20) Lovestone, S., C. L. Hartley, et al. (1996). "Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules." Neuroscience 73(4): 1145-57.
_19_ (8) Mandelkow, E. M., J. Biemat, et al. (1995). "Tau domains, phosphorylation, and interactions with microtubules." Neurobiology of Aging 16(3): 355-62;
discussion 362-3.
(49j Matsubara, M., M. Kusubata, et al. (1996). "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions." Journal of Biological Chemistry 271(35): 21108-13.
(23) Michel, G., M. Mercken, et al. (1998). "Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23j transfected cells:' Biochimica et Biophysics Acta 1380(2): 177-82.
(40) Nikolic, M., M. M. Chou, et al. (1998). "The p35/CdkS kinase is a neuron-specific Rac effector that inhibits Pak1 activity." Nature 395(6698): 194-8.
(39) Nikolic, M., H. Dudek, et al. (1996). "The cdk51p35 kinase is essential for neurite outgrowth during neuronal differentiation." Genes & Development 10(7):
816-25.
(35) Ohshima, T., J. M. Ward, et al. (1996). "Targeted disruption of the cyclin dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death." Proceedings of the National Academy of Sciences of the United States of America 93(20): 11173-8.
(41 j Paglini, G., G. Pigino, et al. (1998). "Evidence for the participation of the neuron-specific cdk5 activator p35 during laminin-enhanced axonal growth."
Journal of Neurscience 18:9858-69.
(48) Pant, A. C., Veeranna, et al. (1997). "Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (cdk5)." Brain Research 765(2): 259-66.
(34) Patrick, G. N., P. Zhou, et al. (1998). "p35, the neuronal-specific activator of cyclin-dependent kinase 5 (CdkS) is degraded by the ubiquitin-proteasome pathway:' Journal of Biological Chemistry 273(37): 24057-64.
(43) Paudel, H. K. (1997j. "Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro." Journal of Biological Chemistry 272(45): 28328-34.
(42) Paudel, H. K., J. Lew, et al. (1993). "Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments." Journal of Biological Chemistry 268(31 ): 23512-8.
(53) Pei, J. J., I. Grundke-Iqbal, et al. (1998). "Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration." Brain Research 797(2): 267-77.
(12) Poorkaj, P., T. D. Bird, et al. (1998). "Tau is a candidate gene for chromosome 17 frontotemporal dementia." Annals of Neurology 43(6): 815-25.
(29) Qi, Z., Q. Q. Huang, et al. (1995). "Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed CdkS and an active fragment of the brain-specific activator.
Kinase activation in the absence of CdkS phosphorylation:' Journal of Biological Chemistry 270( 18): 10847-54.
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16th ed., 1982 Sambrook, J., E.F. Fritsch et al. "Molecular Cloning: A Laboratory Manual".
2nd ed., Cold Spring Harbor Press, New York, 1989 (1 ) Selkoe, D. (1998) "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease." Trends in Cell Biology 8: 447-53.
(50) Shuang, R., L. Zhang, et al. (1998). "Regulation of Munc-18/syntaxin 1A
interaction by cyclin-dependent kinase 5 in nerve endings." Journal of Biological Chemistry 273(9): 4957-66.
(19) Sperber, B. R., S. Leight, et al. (1995). "Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells." Neuroscience Letters 197(2): 149 53.
(4) Spillantini, M. G. and M. Goedert (1998). "Tau protein pathology in neurodegenerative diseases." Trends in Neurosciences 21 (10): 428-433.
(13) Spillantini, M. G., J. R. Murrell, et al. (1998). "Mutation in the tau gene in familial multiple system tauopathy with presenile dementia." Proceedings of the National Academy of Sciences of the United States of America 95(13): 7737-41.
(47) Sun, D., C. L. Leung, et al. (1996). °Phosphorylation of the high molecular weight neurofilament protein (NF-H) by CdkS and p35." Journal of Biological Chemistry 271 (24): 14245-51.
(33) Tang, D., A. C. S. Chun, et al. (1997). "Cyclin-dependent kinase 5 (CdkS) activation domain of neuronal CdkS activator. Evidence of the existence of cyclin fold in neuronal CdkSa activator." Journal of Biological Chemistry 272(19): 12318-27.
(25) Tang, D., K. Y. Lee, et al. (1996). "Neuronal Cdc2-like kinase: from cell cycle to neuronal function." Biochemistry & Cell Biology 74(4): 419-29.
(26) Tang, D. and J. H. Wang (1996). "Cyclin-dependent kinase 5 (CdkS) and neuron-specific Cdk5 activators." Progress in Cell Cycle Research 2: 205-16.
(30) Tang, D., J. Yeung, et al. (1995). "An isoform of the neuronal cyclin-dependent kinase 5 (CdkS) activator." Journal of Biological Chemistry 270(45):
26897-903.
(38) Tomizawa, K., H. Matsui, et al. (1996). "Localization and developmental changes in the neuron-specific cyclin-dependent kinase 5 activator (p35nck5a) in the rat brain." Neuroscience 74(2): 519-29.
(27) Tsai, L. H., I. Delalle, et al. (1994). "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5:' Nature 371 (6496): 419-23.
(37) Tsai, L. H., T. Takahashi, et al. {1993). "Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system." Development 119(4):
1029-40.
(56) Wagner, T. E., P. C. Hoppe, et al. (1981 ). "Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring."
Proceedings of the National Academy of Sciences of the United States of America 78(10):
6376-80.
(24) Wagner, U., J. Brownlees, et al. (1997). "Overexpression of the mouse dishevelled-1 protein inhibits GSK-3beta-mediated phosphorylation of tau in transfected mammalian cells." FEBS Letters 411 (2-3): 369-72.
(21 ) Wagner, U., M. Utton, et al. (1996). "Cellular phosphorylation of tau by beta influences tau binding to microtubules and microtubule organisation."
Journal of Cell Science 109(Pt 6): 1537-43.
(52) Yamaguchi, H., K. Ishiguro, et al. (1996). "Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) (/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II." Acta Neuropathologica 92(3):
232-41.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Pfizer Products Inc.
(ii) TITLE OF INVENTION: Method of Preparing A Tranagenic Non-Human Animal Expressing p25 (iii) NUMBER OF SEQUENCES: 7 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: BERESKIN & PARR
(B) STREET: 40 King Street West (C) CITY: Toronto (D) STATE: Ontario (E) COUNTRY: Canada (F) ZIP: M5H 3Y2 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: iMac - Using Virtual PC
(C) OPERATING SYSTEM: Windows X95 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-FEB-2000 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/118,478 (B) FILING DATE: 03-FEB-1999 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Gravelle, Micheline (B) REGISTRATION NUMBER: 40,261 (C) REFERENCE/DOCKET NUMBER: 10986-73 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (416) 364-7311 (B) TELEFAX: (416) 361-1398 (2) INFORMATION FOR SEQ ID N0:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1867 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
TTCGAGCTCC TATGGTGGTA
TCCTCTGCTC
TCCAAATATA
TTGCACGGCA
AGGCTGGTCC
ACAAAGGAAG
CGACCTCATA
CCTGCCCAAG
CCGCCAGGAG
GGACGAGGAC
AGAACTCGAC
GCCTGCAGGG
ACGCGGGAGG
GAGAGGCTCA
GAGGGAGGCA
TGAACCCTGA
CCAGGGAAAA
AGGCGAAAGG
GACTGAGAGG
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE
CHARACTERISTICS:
(A) LENGTH: 650 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY:
linear (ii) MOLECULE
TYPE: other nucleic acid (xi) SEQUENCE
DESCRIPTION:
SEQ ID N0:2:
ACCCCCGGCC
CCCTCACCCT
CAGTGAGCTG
CCTGTCCCCC
GGGCTGGCAG
CAGGGATGTT
ATGCCTGTAC
CCTGGTGGAG
GAGCTCAAAG
CCTGAAGAAC
AGGCGGCCGC
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 717 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0:3:
GGAACCTTAC
TAAGGTAAAT
TGTATTTTAG
TGAGGAAAAC
CTCTCAACAT
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3218 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE
DESCRIPTION:
SEQ
ID
N0:4:
TATGGTGGTA
TCCAAATATA
TTGCACGGCA
AGGCTGGTCC
ACAAAGGAAG
CGACCTCATA
CCTGCCCAAG
CCGCCAGGAG
GGACGAGGAC
AGAACTCGAC
GCCTGCAGGG
ACGCGGGAGG
GAGAGGCTCA
GAGGGAGGCA
TGAACCCTGA
CCAGGGAAAA
AGGCGAAAGG
GGTAGGGCAC
AGAACTCATA
GATGTTCCTT
GGTCATCTCT
CAGATCCGAG
GGCTGTGATG
TCGTGAACCC
AATAAGGGGA
TATGGGGTTG
CACCACCACC
CGGGTCACAT
CTGGGAGCCG
CCGCCACCGG
GAATTGGTCG
GCCAGCTCTC
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2462 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0:5:
CAGGTCGACT
GCCGGTCTCC
AATCGGCCAA
CACTGACTCG
GGTAATACGG
CCAGCAAAAG
CCCCCCTGAC
ACTATAAAGA
CCTGCCGCTT
ATGCTCACGC
GCACGAACCC
CAACCCGGTA
AGCGAGGTAT
TAGAAGGACA
TGGTAGCTCT
GTCTGACGCT
AAGGATCTTC
ATATGAGTAA
GATCTGTCTA
ACGGGAGGGC
GGCTCCAGAT
TGCAACTTTA
TTCGCCAGTT
CTCGTCGTTT
ATCCCCCATG
TAAGTTGGCC
CATGCCATCC
ATAGTGTATG
ACATAGCAGA
AAGGATCTTA
TTCAGCATCT
CGCAAAAAAG
ATATTATTGA
TTAGAAAAAT
CTAAGAAACC
TCGTCTCGCG
GGTCACAGCT
GGGTGTTGGC
AGTGCACCAT
TATCATACAC
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base fairs {B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0;6:
AGCCGCCTGC
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base fairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Letters 307(2): 199-205.
(44) Hasegawa, M., R. A. Crowther, et al. (1997). "Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans.
Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation." Journal of Biological Chemistry 272(52): 33118-24.
Hogan, B. et al. "Manipulating the Mouse Embryo: A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratories, New York, 1994.
(22) Hong, M., D. C. Chen, et al. (1997). "Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3." Journal of Biological Chemistry 272(40): 25326-32.
(15) Hong, M., V. Zhukareva, et al. (1998). "Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary FTDP-17." Science 282: 1914-1917.
(14) Hutton, M., C. L. Lendon, et al. (1998). "Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17." Nature 393(6686): 702-5.
(16) Imahori, K. and T. Uchida (1997). "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease." Journal of Biochemistry 121(2):
179-88.
(18) Ishiguro, K., M. Takamatsu et al. (1992). "Tau protein kinase t converts normal tau protein into A68-like component of paired helical filaments."
Journal of Biological Chemistry 267:10897-901.
(10) Kampers, T., P. Friedhoff, et al. (1996). "RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments." FEBS Letters 399(3): 344-9.
(57) Laemmli, U. K. (1970). "Cleavage of structural proteins during the assembly of the head of bacteriophage T4." Nature 227(259): 680-5.
(51 ) Lee, K. Y., C. C. Helbing, et al. (1997). "Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein." Journal of Biological Chemistry 272(9):
5622-6.
(28) Lew, J., Q. Q. Huang, et al. (1994). "A brain-specific activator of cyclin-dependent kinase 5." Nature 371 (6496): 423-6.
(46) Lew, J., R. J. Winkfein, et al. (1992). "Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2."
Journal of Biological Chemistry 267(36): 25922-6.
(20) Lovestone, S., C. L. Hartley, et al. (1996). "Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules." Neuroscience 73(4): 1145-57.
_19_ (8) Mandelkow, E. M., J. Biemat, et al. (1995). "Tau domains, phosphorylation, and interactions with microtubules." Neurobiology of Aging 16(3): 355-62;
discussion 362-3.
(49j Matsubara, M., M. Kusubata, et al. (1996). "Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions." Journal of Biological Chemistry 271(35): 21108-13.
(23) Michel, G., M. Mercken, et al. (1998). "Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase-5 activator (p23j transfected cells:' Biochimica et Biophysics Acta 1380(2): 177-82.
(40) Nikolic, M., M. M. Chou, et al. (1998). "The p35/CdkS kinase is a neuron-specific Rac effector that inhibits Pak1 activity." Nature 395(6698): 194-8.
(39) Nikolic, M., H. Dudek, et al. (1996). "The cdk51p35 kinase is essential for neurite outgrowth during neuronal differentiation." Genes & Development 10(7):
816-25.
(35) Ohshima, T., J. M. Ward, et al. (1996). "Targeted disruption of the cyclin dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death." Proceedings of the National Academy of Sciences of the United States of America 93(20): 11173-8.
(41 j Paglini, G., G. Pigino, et al. (1998). "Evidence for the participation of the neuron-specific cdk5 activator p35 during laminin-enhanced axonal growth."
Journal of Neurscience 18:9858-69.
(48) Pant, A. C., Veeranna, et al. (1997). "Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (cdk5)." Brain Research 765(2): 259-66.
(34) Patrick, G. N., P. Zhou, et al. (1998). "p35, the neuronal-specific activator of cyclin-dependent kinase 5 (CdkS) is degraded by the ubiquitin-proteasome pathway:' Journal of Biological Chemistry 273(37): 24057-64.
(43) Paudel, H. K. (1997j. "Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro." Journal of Biological Chemistry 272(45): 28328-34.
(42) Paudel, H. K., J. Lew, et al. (1993). "Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments." Journal of Biological Chemistry 268(31 ): 23512-8.
(53) Pei, J. J., I. Grundke-Iqbal, et al. (1998). "Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration." Brain Research 797(2): 267-77.
(12) Poorkaj, P., T. D. Bird, et al. (1998). "Tau is a candidate gene for chromosome 17 frontotemporal dementia." Annals of Neurology 43(6): 815-25.
(29) Qi, Z., Q. Q. Huang, et al. (1995). "Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed CdkS and an active fragment of the brain-specific activator.
Kinase activation in the absence of CdkS phosphorylation:' Journal of Biological Chemistry 270( 18): 10847-54.
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16th ed., 1982 Sambrook, J., E.F. Fritsch et al. "Molecular Cloning: A Laboratory Manual".
2nd ed., Cold Spring Harbor Press, New York, 1989 (1 ) Selkoe, D. (1998) "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease." Trends in Cell Biology 8: 447-53.
(50) Shuang, R., L. Zhang, et al. (1998). "Regulation of Munc-18/syntaxin 1A
interaction by cyclin-dependent kinase 5 in nerve endings." Journal of Biological Chemistry 273(9): 4957-66.
(19) Sperber, B. R., S. Leight, et al. (1995). "Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells." Neuroscience Letters 197(2): 149 53.
(4) Spillantini, M. G. and M. Goedert (1998). "Tau protein pathology in neurodegenerative diseases." Trends in Neurosciences 21 (10): 428-433.
(13) Spillantini, M. G., J. R. Murrell, et al. (1998). "Mutation in the tau gene in familial multiple system tauopathy with presenile dementia." Proceedings of the National Academy of Sciences of the United States of America 95(13): 7737-41.
(47) Sun, D., C. L. Leung, et al. (1996). °Phosphorylation of the high molecular weight neurofilament protein (NF-H) by CdkS and p35." Journal of Biological Chemistry 271 (24): 14245-51.
(33) Tang, D., A. C. S. Chun, et al. (1997). "Cyclin-dependent kinase 5 (CdkS) activation domain of neuronal CdkS activator. Evidence of the existence of cyclin fold in neuronal CdkSa activator." Journal of Biological Chemistry 272(19): 12318-27.
(25) Tang, D., K. Y. Lee, et al. (1996). "Neuronal Cdc2-like kinase: from cell cycle to neuronal function." Biochemistry & Cell Biology 74(4): 419-29.
(26) Tang, D. and J. H. Wang (1996). "Cyclin-dependent kinase 5 (CdkS) and neuron-specific Cdk5 activators." Progress in Cell Cycle Research 2: 205-16.
(30) Tang, D., J. Yeung, et al. (1995). "An isoform of the neuronal cyclin-dependent kinase 5 (CdkS) activator." Journal of Biological Chemistry 270(45):
26897-903.
(38) Tomizawa, K., H. Matsui, et al. (1996). "Localization and developmental changes in the neuron-specific cyclin-dependent kinase 5 activator (p35nck5a) in the rat brain." Neuroscience 74(2): 519-29.
(27) Tsai, L. H., I. Delalle, et al. (1994). "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5:' Nature 371 (6496): 419-23.
(37) Tsai, L. H., T. Takahashi, et al. {1993). "Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system." Development 119(4):
1029-40.
(56) Wagner, T. E., P. C. Hoppe, et al. (1981 ). "Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring."
Proceedings of the National Academy of Sciences of the United States of America 78(10):
6376-80.
(24) Wagner, U., J. Brownlees, et al. (1997). "Overexpression of the mouse dishevelled-1 protein inhibits GSK-3beta-mediated phosphorylation of tau in transfected mammalian cells." FEBS Letters 411 (2-3): 369-72.
(21 ) Wagner, U., M. Utton, et al. (1996). "Cellular phosphorylation of tau by beta influences tau binding to microtubules and microtubule organisation."
Journal of Cell Science 109(Pt 6): 1537-43.
(52) Yamaguchi, H., K. Ishiguro, et al. (1996). "Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) (/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II." Acta Neuropathologica 92(3):
232-41.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Pfizer Products Inc.
(ii) TITLE OF INVENTION: Method of Preparing A Tranagenic Non-Human Animal Expressing p25 (iii) NUMBER OF SEQUENCES: 7 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: BERESKIN & PARR
(B) STREET: 40 King Street West (C) CITY: Toronto (D) STATE: Ontario (E) COUNTRY: Canada (F) ZIP: M5H 3Y2 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: iMac - Using Virtual PC
(C) OPERATING SYSTEM: Windows X95 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-FEB-2000 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/118,478 (B) FILING DATE: 03-FEB-1999 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Gravelle, Micheline (B) REGISTRATION NUMBER: 40,261 (C) REFERENCE/DOCKET NUMBER: 10986-73 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (416) 364-7311 (B) TELEFAX: (416) 361-1398 (2) INFORMATION FOR SEQ ID N0:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1867 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
TTCGAGCTCC TATGGTGGTA
TCCTCTGCTC
TCCAAATATA
TTGCACGGCA
AGGCTGGTCC
ACAAAGGAAG
CGACCTCATA
CCTGCCCAAG
CCGCCAGGAG
GGACGAGGAC
AGAACTCGAC
GCCTGCAGGG
ACGCGGGAGG
GAGAGGCTCA
GAGGGAGGCA
TGAACCCTGA
CCAGGGAAAA
AGGCGAAAGG
GACTGAGAGG
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE
CHARACTERISTICS:
(A) LENGTH: 650 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY:
linear (ii) MOLECULE
TYPE: other nucleic acid (xi) SEQUENCE
DESCRIPTION:
SEQ ID N0:2:
ACCCCCGGCC
CCCTCACCCT
CAGTGAGCTG
CCTGTCCCCC
GGGCTGGCAG
CAGGGATGTT
ATGCCTGTAC
CCTGGTGGAG
GAGCTCAAAG
CCTGAAGAAC
AGGCGGCCGC
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 717 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0:3:
GGAACCTTAC
TAAGGTAAAT
TGTATTTTAG
TGAGGAAAAC
CTCTCAACAT
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3218 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE
DESCRIPTION:
SEQ
ID
N0:4:
TATGGTGGTA
TCCAAATATA
TTGCACGGCA
AGGCTGGTCC
ACAAAGGAAG
CGACCTCATA
CCTGCCCAAG
CCGCCAGGAG
GGACGAGGAC
AGAACTCGAC
GCCTGCAGGG
ACGCGGGAGG
GAGAGGCTCA
GAGGGAGGCA
TGAACCCTGA
CCAGGGAAAA
AGGCGAAAGG
GGTAGGGCAC
AGAACTCATA
GATGTTCCTT
GGTCATCTCT
CAGATCCGAG
GGCTGTGATG
TCGTGAACCC
AATAAGGGGA
TATGGGGTTG
CACCACCACC
CGGGTCACAT
CTGGGAGCCG
CCGCCACCGG
GAATTGGTCG
GCCAGCTCTC
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2462 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0:5:
CAGGTCGACT
GCCGGTCTCC
AATCGGCCAA
CACTGACTCG
GGTAATACGG
CCAGCAAAAG
CCCCCCTGAC
ACTATAAAGA
CCTGCCGCTT
ATGCTCACGC
GCACGAACCC
CAACCCGGTA
AGCGAGGTAT
TAGAAGGACA
TGGTAGCTCT
GTCTGACGCT
AAGGATCTTC
ATATGAGTAA
GATCTGTCTA
ACGGGAGGGC
GGCTCCAGAT
TGCAACTTTA
TTCGCCAGTT
CTCGTCGTTT
ATCCCCCATG
TAAGTTGGCC
CATGCCATCC
ATAGTGTATG
ACATAGCAGA
AAGGATCTTA
TTCAGCATCT
CGCAAAAAAG
ATATTATTGA
TTAGAAAAAT
CTAAGAAACC
TCGTCTCGCG
GGTCACAGCT
GGGTGTTGGC
AGTGCACCAT
TATCATACAC
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base fairs {B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ
ID N0;6:
AGCCGCCTGC
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base fairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Claims (2)
1. A transgenic non-human mammal and progeny thereof whose germ cells and somatic cells express recombinant DNA comprising a neuron specific enolase promoter operably linked to a p25 encoding sequence, wherein said transgenic non-human mammal has increased brain total tau protein, increased brain tau phosphorylation, increased brain neurofilament H phosphorylation, or increased neuronal silver staining, as compared to a control non-human mammal.
2. A transgenic non-human mammal and progeny thereof according to claim 1 which is a mouse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11847899P | 1999-02-03 | 1999-02-03 | |
US60/118,478 | 1999-02-03 | ||
CA002295861A CA2295861C (en) | 1999-02-03 | 2000-02-03 | Method of preparing a transgenic non-human animal expressing p25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002295861A Division CA2295861C (en) | 1999-02-03 | 2000-02-03 | Method of preparing a transgenic non-human animal expressing p25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2468453A1 true CA2468453A1 (en) | 2000-08-03 |
Family
ID=32991589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002468453A Abandoned CA2468453A1 (en) | 1999-02-03 | 2000-02-03 | Method of preparing a transgenic non-human animal expressing p25 |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2468453A1 (en) |
-
2000
- 2000-02-03 CA CA002468453A patent/CA2468453A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Von Koch et al. | Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice | |
Brion et al. | Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease | |
US9161520B2 (en) | Transgenic animal expressing Alzheimer's tau protein | |
Takahashi et al. | Impaired spermatogenic ability of testicular germ cells in mice deficient in the LIM-kinase 2 gene | |
EP1870472B1 (en) | Model animal of Alzheimer's disease and use thereof | |
US7161060B1 (en) | Transgenic mice comprising a genomic human tau transgene | |
Umland et al. | The use of yeast artificial chromosomes for transgenesis | |
US6452065B2 (en) | Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background | |
AU782281B2 (en) | Transgenic animals as models for neurodegenerative disease | |
CA2295861C (en) | Method of preparing a transgenic non-human animal expressing p25 | |
US6693226B1 (en) | Transgenic mice expressing human p25 | |
US20040154047A1 (en) | Gene-targeted non-human mammal with human FAD presenilin mutation and generational offspring | |
AU2001262482B2 (en) | Model for neurodegenerative disease | |
CA2468453A1 (en) | Method of preparing a transgenic non-human animal expressing p25 | |
AU2009240404A1 (en) | Abi1/Hssh3bp1 conditional knockout mouse | |
JP5046413B2 (en) | Targeted recombinant non-human mammal with human FAD presenilin mutation and reproductive progeny | |
US20060168673A1 (en) | Transgenic animals as models for neurodegenerative disease | |
MXPA00001318A (en) | Transgenic animals expressing human p25 | |
US8993833B2 (en) | Model of Alzheimer's Disease | |
AU2001262482A1 (en) | Model for neurodegenerative disease | |
US20060015959A1 (en) | Transgenic animals expressing transglutaminase II | |
ZA200110477B (en) | Transgenic animals as models for neurodegenerative disease. | |
DE60223205T2 (en) | Transgenic animal model for Alzheimer's disease | |
Hernández Pérez et al. | Model for neurodegenerative diseases | |
Von Koch | Molecular analysis of a homologue of the mouse beta-amyloid precursor protein, APLP2: Isolation of APLP2cDNA, characterization of the APLP2 gene promoter and gene targeting of APLP2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |